Neurological complications after stem cell transplantation in children by Rubin, Johanna
 From the Department of Clinical Science, Intervention and 
Technology, Division of Pediatrics, 
Karolinska Institutet, Stockholm, Sweden 
 
 
 
 
 
NEUROLOGICAL COMPLICATIONS 
AFTER STEM CELL TRANSPLANTATION 
IN CHILDREN 
 
 
Johanna Rubin 
 
 
 
 
 
 
 
 
 
Stockholm 2011
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover drawing Primus Rubin 2011 
 
All previously published papers were reproduced with permission from the publisher. 
 
Published by Karolinska Institutet. Printed by Larserics Printing AB. 
 
© Johanna Rubin, 2011 
 
ISBN 978-91-7457-268-1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  To all parents,  
struggling, worrying, never losing hope,  
to all of you who wish to become one and  
to Primus, who made my greatest wish come true. 
  
 
  
ABSTRACT 
Allogeneic haematopoietic stem cell transplantation (HSCT) is a well established 
method used in the treatment of a number of benign and malignant blood diseases, 
inborn errors of metabolism and severe congenital immunodeficiency syndromes. 
Around 60 children are transplanted in Sweden every year. Every HSCT carries a risk 
of different types of complications for the patient. As the success rate and survival after 
HSCT increases, the prevention of neurological complications and their long-term 
sequelae has particular significance in the paediatric patient group. 
Paper I describes the acute neurological complications after HSCT in144 paediatric 
patients transplanted between 1995 and 2002 at the Karolinska University Hospital-
Huddinge. The group of 19 patients (13%) who suffered from neurological 
complications within three months after HSCT had an elevated risk of death within the 
first year after HSCT. An increasing number of positive herpesvirus serologies and 
CMV sero-positivity before HSCT as well as electrolyte-disturbances, high blood 
pressure and elevated bilirubin during the first three months after HSCT increased the 
risk of neurological complications. The most common complication was seizures and 
the most frequent causes of these complications were infection and encephalopathy. In 
several patients the exact aetiology of the complication could not be determined. 
Intrathecal chemotherapy is given as prophylaxis to high risk patients after HSCT to 
lower the risk of CNS relapse of malignant disease. The treatment increases the risk for 
acute and late onset neurological complications. However the need for this treatment is 
questioned as advances in primary oncologic treatment before HSCT has substantially 
decreased the risk for CNS relapse. In Paper II and III we retrospectively compared 
patients who received intrathecal therapy after HSCT to a group who was not given this 
treatment. The primary aim was to examine if there was a reduction in CNS relapses in 
the group given intrathecal chemoprophylaxis. In Paper II 120 patients transplanted 
1992 to 2005 were included in the study. In Paper III 397 patients transplanted 1992 to 
2006 were studied. Neither of the studies could identify a difference in the prevalence 
of CNS relapses, other types of relapses, mortality or a difference in the prevalence of 
neurological complications between the two groups. The study results have resulted in 
a revision of the clinical protocol for intrathecal chemoprophylaxis after HSCT in many 
centres. 
In Paper IV we addressed the fact that infections are a common cause of neurological 
complications after HSCT and that the exact cause of many complications are 
unknown. We aimed to study the prevalence and the clinical symptoms of CNS 
infections by human polyomavirus (HPyV) within a year after HSCT. We analysed 
retrospectively the CSF of 20 HSCT patients with neurological complications for five 
different HPyV; JC-, BK-, KI-, WU-, and MCPyV. JC- and BK-PyV are known 
neurotropic viruses discovered in the 1970`s. KI-, WU- and MCPyV are more recently 
discovered viruses where the neurotropic ability is not yet known. The PCR analyses of 
the 20 CSF-samples were negative for all the five viruses. More studies need to be done 
to determine the significance of the new HPyV in complications after HSCT. 
Conclusion: our studies have contributed with a small piece of knowledge in the 
struggle to prevent neurological complications after HSCT. Further research is though 
needed to identify additional risk factors and further improve treatment so that less 
neurotoxic treatments are needed.   
  
 
 
  
LIST OF PUBLICATIONS 
The thesis is based on the following papers, which will be referred to by their Roman 
numerals (I-IV): 
 
 
 
I.  Acute neurological complications after hematopoietic stem cell transplantation 
in children. Rubin J, Wide K, Remberger M, Gustafsson B. Pediatric 
Transplantation 2005; 9 (1), 62-67.  
 
II.  Intrathecal chemotherapy after HSCT in children. Rubin J, Frost B-M, 
Arvidson J, Wide K, Gustafsson-Jernberg Å, Gustafsson B. Pediatric 
Transplantation 2008; 12 (8), 889-895. 
 
III.  Use of intrathecal chemoprophylaxis in children after SCT and the risk of 
central nervous system relapse. J Rubin, K Vettenranta, J Vettenranta, 
M Bierings, J Abrahamsson, A N Békássy, Y Håkansson, B-M Frost, 
J Arvidson, C Spendilow, J Winiarski and B Gustafsson. Bone Marrow 
Transplantation 2011; 46 (3), 372-378.  
 
IV.  Human polyomaviruses were not detected in cerebrospinal fluid of patients 
with neurological complications after hematopoetic stem cell transplantation 
Rubin J, Giraud G, Priftakis P, Wide K, Gustafsson B, Ramqvist T, Dalianis 
T. Manuscript. 
 
  
 
  
CONTENTS 
Introduction .......................................................................................................... 1 
History .................................................................................................................. 2 
Hematopoietic Allogeneic Stem Cell Transplantation ................................ 7 
Indications ........................................................................................... 7 
Choosing the donor and stem cell source .......................................... 8 
Conditioning treatment ....................................................................... 9 
Prophylaxis against GVHD .............................................................. 11 
Prophylaxis against infectious complications .................................. 11 
Prophylaxis against CNS relapse: Intrathecal therapy .................... 12 
Complications following HSCT ....................................................... 13 
Graft versus host disease .................................................................. 13 
The graft versus tumour effect ......................................................... 16 
Infectious complications ................................................................... 16 
Relapse after HSCT .......................................................................... 23 
Secondary malignancies ................................................................... 25 
Endocrine complications .................................................................. 26 
Neurological complications .............................................................. 26 
Aims of the thesis ............................................................................................... 33 
Patients, material and methods .......................................................................... 35 
Patients and material ................................................................................... 35 
Patients and material, Paper I ........................................................... 35 
Patients and material, Paper II and III .............................................. 35 
Patients and material, Paper IV ........................................................ 37 
Methods ...................................................................................................... 37 
Methods, Paper I ............................................................................... 38 
Methods, Paper II and III .................................................................. 38 
Methods, Paper IV ............................................................................ 39 
Ethical permissions and considerations ..................................................... 40 
Results ................................................................................................................ 42 
Results, Paper I ................................................................................. 42 
Results, Paper II and III .................................................................... 42 
Results, Paper IV .............................................................................. 45 
Discussion .......................................................................................................... 47 
Closing remarks and future perspectives .......................................................... 53 
Svensk sammanfattning ..................................................................................... 54 
Acknowledgements ............................................................................................ 56 
References .......................................................................................................... 59 
 
  
LIST OF ABBREVIATIONS 
 
ADA Adenosine deaminase deficiency 
aGVHD Acute graft versus host disease 
ALL Acute lymphoblast leukaemia 
AML Acute myeloid leukaemia  
ARDS Acute respiratory distress syndrome 
ATG Antithymocyte globulin 
BFM Berlin-Frankfurt-Munich group 
BM Bone marrow 
BO Bronchiolitis obliterans 
CAST Centre for Allogeneic Stem Cell Transplantation, Karolinska 
CB Cord blood 
cGVHD Chronic graft versus host disease 
CML Chronic myelogenous leukaemia 
CMML Chronic myelomonocytic leukaemia 
CMV Cytomegalovirus 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CT Computed tomography 
CVD Cerebrovascular disease 
DAD Diffuse alveolar damage 
DCOG Dutch Childhood Oncology Group 
DLI Donor lymphocyte infusion 
DNA Deoxyribonucleic acid  
EBV Epstein –Barr virus 
EEG Electroencephalogram 
FHL Familial Haemophagocytic Lymphohistiocytosis 
FLAIR Fluid attenuation inversion recovery 
GI Gastrointestinal 
GVHD Graft versus host disease 
GVL Graft versus leukaemia 
Gy Grey 
HBV Hepatitis B virus 
HC Haemorrhagic cystitis 
HHV-6 Human herpes virus 6 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HPyV Human polyomavirus 
HRT Hormone replacement therapy 
HSCT Allogeneic haematopoietic stem cell transplantation 
HSV Herpes simplex virus 
ICH Intracranial haemorrhage 
JMML Juvenile myelomonocytic leukaemia 
LIP Lymphocytic interstitial pneumonia 
LP Lumbar puncture 
  
MDS Myelodysplastic syndrome 
MRD Minimal residual disease 
MRI Magnetic resonance imaging 
MSD Matched sibling donor 
MUD Matched unrelated donor 
NK cells Natural killer cells 
NOPHO Nordic Society of Paediatric Oncology and Haematology 
Ph+ALL Philadelphia chromosome positive ALL 
PRES Posterior reversible encephalopathy syndrome 
PBSC Peripheral blood stem cells 
PTLD Post transplant lymphoproliferative disease  
PTM Post transplant malignancies 
PyV Polyomavirus  
RIC Reduced intensity conditioning 
RSV Respiratory syncytial 
SCID Severe combined immunodeficiency 
SD Standard deviation 
SOS Sinusoidal obstruction syndrome 
t-AML Treatment related AML 
TBI Total body irradiation 
VOD Veno-occlusive disease 
VZV Varicellae zoster virus 
WAS Wiskott-Aldrich syndrome 
X-linked SCID X-chromosome-linked severe combined immunodeficiency 
  
  
  
  
 
   1 
INTRODUCTION 
Allogeneic haematopoietic stem cell transplantation (HSCT) is a lifesaving method of 
treatment used in paediatric medicine to treat a number of benign and malign blood 
disorders as well as certain inborn errors of metabolism and severe congenital 
immunodeficiency syndromes. However, the procedure is associated with a number of 
life-threatening complications with the risk of long-term sequelae. Avoiding 
complications involving the central nervous system is of special importance for 
developing children. As the success rate of, and survival after HSCT increases, the 
prevention of neurological complications and their long-term sequelae has particular 
significance.  
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HISTORY 
The first successful allogeneic stem cell transplantations were performed in 1968 after a 
few decades of isolated attempts with many failures. Gatti and Bach independently 
reported two cases of successful transplantations, in the same issue of The Lancet in 
December 1968. Gatti reported the case of a 5 months old boy with “sex-linked 
lymphopenic immune deficiency”, today known as X-linked severe immunodeficiency, 
or X-linked SCID. The boy received leucocytes from blood and stem cells from his 
sister‟s bone marrow intraperitoneally (BM). He did not receive any pre-treatment. 
Bach reported the case of a 22 months old boy with Wiskott-Aldrich syndrome (WAS). 
He was given his sister‟s BM stem cells without conditioning treatment, resulting in 
failure of the transplantation. Prior to the next stem cell infusion, he received a four-day 
course of cyclophosphamide, which resulted in engraftment. (1, 2).  In Sweden, the first 
allogenic stem cell transplantation was performed in a 17 years old patient with aplastic 
anaemia in 1975 at the Karolinska University Hospital Huddinge (3).  During 1975 to 
1986 74 paediatric patients were transplanted at the Karolinska University Hospital 
Huddinge (4).What was an experimental procedure 50 years ago is now a well 
established treatment method with over 10.000 allogeneic HSCT per year in Europe (5) 
and 250 per year in Sweden. Out of these 60 are performed on paediatric patients (6). 
The modern allogeneic HSCT procedure contains two phases; first the conditioning 
phase when chemotherapy is given, sometimes combined with total body irradiation 
(TBI), then the patient receive an infusion of stem cells from a donor. Within the 
following weeks, the stem cells will migrate through the body to attach and proliferate 
in the bone marrow of the recipient. The engraftment of the new cells, which usually 
occurs within two to four weeks after the stem cell infusion, is defined as a stable 
absolute neutrophil count > 0,5 x 10
(9)
cells/L. The survival rate after HSCT in the 
scenario with a well matched donor and a benign disease is now very high. As an 
example, patients diagnosed with thalassemia major transplanted with a fully matched 
sibling donor has an 8-year overall survival of 94.5% and an 8-year disease free 
survival of above 80% in Europe (7).The survival rate of children with malignant 
diseases is lower. This is due to the risk of a relapse in the malignant disease as well as 
often more aggressive treatment choices, including an anti leukaemic treatment and a 
more intensive conditioning therapy for relapsing patients. There is also a difference in 
survival depending on the donor type. The 3 –year survival after HSCT for paediatric 
patients with leukaemia or myelodysplastic syndrome (MDS) is about 60% with a 
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matched sibling donor (MSD) and 50% with a matched unrelated donor (MUD) (8).  
Thanks to the progress of paediatric oncologic treatment and the HSCT procedure the 
outcome of malignant diagnoses are improving fast. A study from 2010 of a patient 
group with mixed indications for HSCT, showed a survival rate of 37% in patients who 
were transplanted 1993-1997 and a survival rate of 53% in patients transplanted 2003-
2007 (9).When considering the increasing survival rates of children with malignant 
diseases, one must take into account the success of paediatric oncologic primary 
treatment where the children with acute lymphoblast leukaemia (ALL) now have a 90% 
5-year survival (10) compared to 70% in the 1980‟s (11). The consequence of this 
success is that the patients currently eligible for HSCT have a more advanced 
malignant disease than previously (9). 
 
The stem cell transplantation procedure contains a number of elements that involve a 
high mortality risk. All patients go through a period of severe immunosuppression with 
the risk of mortal infections; there is a risk of severe drug-related side effects and the 
risk of malignant disease relapse remains for the oncologic patients, although it is 
diminished after HSCT. For paediatric survivors of HSCT the development of 
cognitive and psychomotor skills is naturally of the utmost importance. When 
reviewing literature on neurological complications we can conclude that the risk has 
decreased due to better treatment options. Radiotherapy for patients < 3 years of age is 
now used restrictively both in primary oncologic treatment and in the conditioning 
regimen for HSCT since evidence of more severe neuropsychological sequelae has 
been found in this age group, compared to older children (12-14). The literature on 
neurological complications after stem cell transplantation in children, especially on 
long-term neurological sequelae, is scarce. Although, in recent years, more attention 
has been brought to the subject (Table 1). Several available studies confirm that there is 
an increased mortality risk associated with neurological complications after HSCT (15-
18) (Fig 1.). 
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Fig. 1. Kaplan Meyer survival curve showing the difference in 1-year survival between 
patients suffering from acute neurological complications (appearing within three 
months) after HSCT compared to patients without acute neurological complications (p< 
0.01). Data from Paper I, where 144 paediatric patients transplanted between 1995 and 
2002 were studied. (Time shown as number of days after transplantation.) 
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Table 1. Overview of published studies on the incidence and causes of neurological complications (NC) 
after allogeneic stem cell transplantation (HSCT) in children. (Until  May 2011)    
          
Publ 
year Author 
No of 
patien
ts 
Age 
at 
HS
CT 
Specific 
subgroup 
and/or 
Observation 
time Incidence  
Most common 
symptoms  
Most common 
causes 
Risk 
factors for 
NC if 
specified 
Influence 
on 
survival, if 
specified 
1984 Wiznitzer 57 
6 m 
-24 
yrs 
10 d - 81 
months after 
HSCT 
Total 
59%. 
CNS 35% 
PNS  
14% both 
10%  Not specified 
Infections,CNS 
leukemia, CVD, 
metabolic 
encephalopathy, 
cognitive 
Not 
specified 
All pts 
51%,surv 
median 46 
months  
1990 
van der 
Berg 23 
4-17 
yrs 
Only ALL 
patients 17% 
leukoencephalopat
hy, MR, 
toxoencephalitis 
leukoencephalopat
hy, MR, 
toxoencephalitis  
25% vs 
100% 
1999 Iguchi 
77 
(54 
allo) 
1-17 
yrs  15,80% 
seizures, 
headache, ataxia, 
oculomotor 
paralysis 
 CVD 23 st, Bu  3 
pt CsA 1 pt, FK506 
1 pt, leukoenc 2 pt, 
SIADH 1pt, TBI 1pt 
For allo, 
mud, 
gvhd > 2 
early NC = 
early death 
but over all 
no 
difference 
2002 Faraci  
272 
(185 
allo) 
0.1 - 
19.5 
yrs 
Mean 15 
months. ( 2 d 
to 15.6 yrs) 13,60% 
seizures, impaired 
consciousness, 
motitlitydisorder 
and sensistivity 
disorder, cortical 
function,ivolontary 
movements, visual 
CsA tox , irr/chemo, 
CNS inf, CVD, 
immune mediated 
compl 
HSCT 
type, TBI, 
aGVHD, 
GVHD > 
gr 2, CsA 
Mortality 
30% vs 
8.5% 
2004 Woodard 405 
1-21 
yrs 
Only studied; 
encephalopat
hy  6,40%  
TTP; amphoteicin 
B, seizures, viral 
encephalopathy, 
adem ,liver failure, 
uremia, 
aspergillosis, CVS, 
CyA, MOF  17/26 died 
2005 Rubin 144 
0-18 
yrs 78 d (7-90 d) 13% 
seizures, alt conc, 
headache, paresis,  
infection, 
encephalopathy, 
CVD, unknown. 
electrolyte
s, 
bilirubin, 
CsA, viral 
serologies 
6/19, 7/125 
32% vs 
5% 
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Publ 
year Author 
No of 
patients 
Age at 
HSCT 
Specific 
subgroup 
and/or 
Observation 
time Incidence  
Most common 
symptoms  
Most common 
causes 
Risk 
factors for 
NC if 
specified 
Influence 
on 
survival, if 
specified 
2005 Uckan 113 
1,5 m- 
18 yrs 
Only life-
threathening 
NC studied 9,70% 
seizures, cranial 
nerve palsy, CVD, 
headache 
CyA, CVD, 
hypertension, inf, 
hypomagnesemia, 
busulphan 
GVHD > 
2, MUD, 
AML, 
PSBC 
9% vs 
65% 
2007 
Zaucha-
Prazmo 87 
all 
children 
171 pts 
auto+allo 8% 
neurotox, CVD, 
radikulitis 
CyA, CMV, EBV 
radikulitis , CVD  4 of 7 died 
2008 Schmidt 
904 
(allo 
328) 
all 
children  
8.4% (76 
pt, 82 
NC) 
(14.6% 
48 pt/ 
328) 
Seizures, altered 
conciousness, 
motor dysfunction. 
Infection, toxic, 
unclear, neoplastic, 
vascular, 
methabolic  
18/76 
died, 
mortality 
23.7% 
2008 Weber 
165 (54 
auto) 
3 m-30 
yrs 
42.5 mo 
mean 
24% NC 
40/165, 
30.6% 
34/111 
allo SCT 
severe: 12 
seizures/headache 
2, parkinson like 1, 
somnolence 2, 
aphasia 1, slurred 
speach + vision 1. 
Inf 9, drug 4, CVD 2, 
CNS relapse 2, 
unknown 
encephalopathy 1, 
CsA 1  19 severe 
and 21lighter 
symptoms   
2010 Koh 202 
0-20 
years 
Only early 
NC, 
observation 
time 6 
months 
13,5% 
(N=27 ) 
seizures 15, 
altered 
consciousness 12 
, headache 6, 
motor weakness 2, 
parestesia, 
sensory def 1, 
tremor 1, visual 1. 
CyA tox 16, CNS inf 
2, CVD 2, TMA 2, 
methabolic 
encephalopaty 2, 
irraiation/chemother
apy 1, 
encephalitis/unkown 
1, 
myopathy/unkown 
1.  
aGVHD > 
gr 2, 
donor 
52.1% 5 
yr survival 
vs 64.9% 
2010 Noe 67 
 all 
children 
Only CyA 
tox studied. 
Observation 
time 1005 
days. 6 pt 9% 
seizures,blurred 
vision, confusion CyA tox     
 
NC= neurological complication, allo= allogeneic, auto= autologous, CNS= central nervous system,  
PNS= peripheral nervous system, CsA ciklosporin, CVD=cerebrovascular disease,   
TMA= thrombotic microangophaty, TTP=Thrombotic Thrombocytopenic purpura 
d=days, m=months, yr=years, inf=infection   
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HEMATOPOIETIC ALLOGENEIC STEM CELL TRANSPLANTATION 
 
Indications  
The number of diagnoses for which HSCT is a potential rescue or definitive treatment 
increases continuously (19).  In paediatric HSCT the scope is especially wide as a 
number of congenital diseases are treated in early childhood. The HSCT procedure 
differs depending on the diagnosis treated. In HSCT for benign blood diseases such as 
aplastic anaemia, sickle cell disease, thalassemia, Familial Haemophagocytic 
Lymphohistiocytosis (FHL), Kostmanns disease and severe combined 
immunodeficiency the aim is to replace the recipients‟ malfunctioning haematopoietic 
stem cells with healthy haematopoietic stem cells able to produce healthy functioning 
blood cells. In inborn errors of metabolism the new haematopoietic stem cells will be 
able to produce healthy leucocytes which in their turn can produce the enzymes the 
patient is missing. The conditioning regimen shall eliminate the patient‟s mal-
functioning haematopoietic stem cells with minimum damage to other organ systems 
and the donor cells shall engraft without graft versus host disease. A mixed chimerism, 
i.e a bone marrow where some of the patient‟s cells still survives can be tolerated. In 
these disorders maximum steps are taken to avoid graft versus host disease (GVHD). 
Antithymocyte globulin (ATG) is therefore given to all of these patients irrespective of 
type of donor (20). In malignant blood disorders a more aggressive conditioning 
treatment is often used to eradicate the malignant disease from the recipient which can 
result in a higher frequency of complications. Also in these cases, a certain degree of 
GVHD can be tolerated as a graft versus leukaemia (GVL) effect is wanted. All 
patients with malignant disorders go through primary oncologic treatment for their 
disease before proceeding to HSCT-treatment; the only exception is juvenile 
myelomonocytic leukaemia (JMML) where HSCT is generally considered the only 
treatment with a chance for cure (21). Children with acute myeloid leukaemia (AML) 
are transplanted in first remission if they are diagnosed with cytogenetic unfavourable 
markers. Whereas children in their first remission with ALL, only have HSCT in the 
absence of morphological remission from induction therapy or if high levels of minimal 
residual disease (MRD) still remain after three months of therapy or children diagnosed 
with Phil + ALL (Philadelphia chromosome positive ALL)(22) . For chronic 
myelogenous leukaemia (CML), HSCT is the only curative option and should be done 
within six months in affected children as well as children diagnosed with MDS (23, 
24). The timing of HSCT depends on the response to primary therapy. HSCT has 
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presently rarely been reported in paediatric patients with solid tumours. Among the 
patients, reported as case studies or small case-series, relapsed rhabdomyosarcoma, 
Ewing sarcoma and neuroblastoma are the most common diagnoses (25-27). In 
Germany presently there is an ongoing study for children with high-risk metastatic 
rhabdomyosarcoma using haploidentical HSCT (28). Autologous HSCT is of proved 
benefit in high-risk neuroblastoma and Hodgkins disease and is under investigation for 
advanced stages and relapse of Ewing sarcoma (29).  
 
 
Choosing the donor and stem cell source 
A human leucocyte antigen-identical (HLA-identical) sibling donor is the donor of 
choice for all HSCTs. A closely related donor with a matching HLA type will minimize 
the risk of GVHD and GVHD related complications after the transplantation. This in 
turn will substantially reduce the mortality risk after the transplantation (8). If no such 
donor is available registries of voluntary donors worldwide are searched. At our centre 
a matched unrelated donor should be matched on a minimum of six of the six most 
important alleles from the antigen sites HLA-A,-B and DRB1 and molecular high 
resolution techniques should be used. At many centres HLA C is also included as a 
necessary allele (30).  For children a more extensive matching with an up to 14/14 
match (HLA-A,-B,-C, DRB1,DQA1,DQB1 samt DPA1) is presently used  at the 
Karolinska University Hospital (31). In homozygogous thalassemia, HSCT is 
performed to cure a non-mortal disease. The HSCT with a sibling donor is certainly 
preferable, due to the higher mortality risk of using another type of donor. However, if 
the disease is severe, a non-sibling donor can be considered. In these cases, evaluation 
in clinical protocols is essential.  In aplastic anaemia the treatment of choice is HSCT 
with a matched sibling donor, if available. If a sibling donor is not available, 
immunosuppressive therapy is tried before searching for a matched unrelated donor 
(19). In severe combined immunodeficiencies (except for children with adenosine 
deaminase deficiency, ADA, where enzyme therapy is an option (32)) and metabolic 
diseases there is no alternative to HSCT for cure and the HSCT has to be performed, 
sibling or no sibling available. A syngenic (monozygotic twin-) donor is rare but if 
available it is the optimal donor in treating non-malignant disease, due to the practically 
non-existent risk of GVHD (33, 34). A sibling donor is available in approximately 30% 
of all paediatric HSCTs. In absence of an HLA matched sibling donor or a well-
matched unrelated donor, a relative with not fully matching HLA type might be used – 
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which is referred to as a haplo-identical donor. For most transplantations, the donor 
used is a MUD from one of the donor transplantation registries worldwide (35) .  
 
Initially, stem cell transplantation was equal to bone marrow transplantation, as this 
was the stem cell source used. Now peripheral blood stem cells (PBSC) and cord blood 
(CB) has emerged as alternative sources of stem cells for transplantation. BM is still the 
primary choice for transplantation of benign disorders (19). BM is also the primary 
choice for paediatric patients, where transplantation with PBSC has shown a higher 
frequency of chronic graft versus host disease (cGVHD) and higher mortality risk than 
transplantations with BM. PBSC is the stem cell source of choice for adults as the 
concentration of lymphocytes is much higher than in BM which results in easier 
mobilisation and faster hematopoietic recover (36). CB is the third stem cells source 
used. With CB as stem cell source, some patients will receive CB stored from their 
HLA –matched siblings, whereas others get an unrelated CB donation from a cord 
blood bank. The haematopoietic recovery is slower with CB compared to BM or PBSC 
(37) and there is the disadvantage that there will be no cells left for a potentially 
required donor lymphocyte infusion (DLI). A DLI - treatment is given to the recipient 
as supportive therapy to enhance the engraftment or in the case of threatening rejection 
of the donor cells by the recipient. The DLI can also be given with the intent to prevent 
or treat relapse of malignant disease (19). CB is the only option for patients where a 
sibling or a MUD is not available as the donor pool expands with the tolerance of one 
or two HLA mismatches when CB is given (38, 39). CB transplantation also has a 
lower risk of latent virus transmission and a lower risk of acute GVHD (39-41).  The 
risk for infections, most importantly viral infections, has though been reported to be 
higher in CB transplantation than in PBSC and BM transplantation. This is linked to the 
limited capacity of the CB transplant T-cells and the slow recovery of T-cell function 
(21, 42, 43).  In severe combined immunodeficiencies (SCID) and metabolic diseases 
there is no alternative to HSCT for cure and the HSCT has to be performed sibling or 
no sibling available.  
 
 
Conditioning treatment 
The treatment before the infusion of stem cells- the conditioning treatment- differ with 
underlying disease, age of the patient, treatment centre and the overall health condition 
of the patient. If the patient is elderly, has an impairment of kidney or lung function or 
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the disease progression is not so severe that it justifies the toughest conditioning 
regimen, a reduced intensity conditioning (RIC) can be chosen. In general, children will 
receive full myeloablative conditioning with the maximum chance for cure and a higher 
risk of complications. This is due to the fact that despite the difficult disease they are 
being treated for, the children are generally in good health. CAST, the Centre for 
Allogeneic Stem Cell Transplantation at the Karolinska University Hospital Huddinge 
where the paediatric patients from our centre, participating in all four studies in this 
thesis, are transplanted, follow the international protocols regarding the choice of 
conditioning regimens for HSCT.  Before transplantation the children are treated 
according to the NOPHO (Nordic Society of Paediatric Oncology and Haematology) 
protocols for children. For the conditioning myeloablative protocols containing total 
body irradiation 3 Grey (Gy) x 4 and cyclophosphamide 60 mg /kg are chosen for ALL 
in adults and, at the time for these studies also in children. A full myeloablative 
treatment for children with ALL today consists of TBI 3 Gy x 4 days, etoposide 60 
mg/kg x1, 1 day. If there has been a CNS involvement of ALL intrathecal methotrexate 
1x1 during 2 days is given (44). Children < 3 years are given a regimen without TBI. 
Busulphan and cyklophosphamide is used for AML, CML, MDS, JMML and chronic 
myelomonocytic leukaemia (CMML). Melphalan is added for children < 18 years old, 
with MDS and JMML(45). Reduced intensity regimens of busulphan/fludarabine and 
cylophosphamide/fludarabine are given to, as mentioned above, adult patients with a 
certain few malignant disorders, and to patients with contraindications against full 
myeloablative conditioning. When busulphan is used in the conditioning treatment, 
seizure prophylaxis with clonazepam is given during the conditioning phase (46). A 
RIC treatment can be used in children with diagnosis as Fanconis aplastic anaemia and 
FHL (47, 48). A paediatric RIC treatment may consist of Flu 30mg /m2 for five days 
followed by Cy 10 mg/kg for two days(49) .Two intrathecal injections of methotrexate 
are included in the conditioning regimen for patients with previous CNS AML or ALL 
leukaemia and for all infant ALL patients (44, 50, 51). Other European transplantation 
centres, follow different protocols.  The Utrecht centre, participating in study III, follow 
the Dutch Childhood Oncology Group (DCOG) and the Berlin-Frankfurt-Munich 
treatment protocols with slightly different primary treatment and conditioning 
regimens. As an example the myeloablative conditioning for ALL for children > 2 
years of age, included 2x2 Gy TBI during three consecutive days and thereafter one day 
with a dose of etoposide 60 mg/kg/day, plus local irradiation of the respective areas, if 
involvement of testes or CNS (52). In preparing the studies we concluded that these 
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differences were not sufficient to interfere with the results when studying the effect on 
isolated CNS relapses of intrathecal therapy after HSCT.  
 
 
Prophylaxis against GVHD 
To reduce the risk of GVHD ATG-treatment is given the last days before the infusion 
of stem cells in benign disorders and when the donor is a MUD or a HLA mis-matched 
donor. It is also given in some RIC protocols (20). GVHD-prophylaxis is given to all 
patients from day –1. The most common drugs used are cyclosporine in combination 
with methotrexate. During the six to twelve months after HSCT the patients are seen 
regularly for monitoring of blood cell counts, infections prophylactic treatment, re-
vaccination and observation for and treatment of GVHD. The patient will stay on 
immunosuppressive treatment as primary prophylaxis against GVHD, for up to twelve 
months after HSCT depending on donor, disease and symptoms of GVHD (53). 
 
 
Prophylaxis against infectious complications 
All patients receive infectious prophylaxis against P jiroveci with cotrimoxasole three 
days per week as standard drug until the day of transplantation. Cotrimoxasole is then 
re-introduced after engraftment and continued until six months after HSCT – or if 
later- until the end of immunosuppressive treatment or resolution of GVHD disease. 
If the patient is toxoplasma gondii antibody positive a daily dose of cotrimoxasole is 
given. After conditioning, during the neutropenic phase, ciprofloxacin is used as 
antibacterial prophylaxis and nystatin and fluconazole as fungal prophylaxis. This 
treatment is started after the conditioning phase and continued until engraftment. 
Additional viral prophylaxis is prescribed if the patient is herpes simplex virus (HSV) 
positive with a HSV titre of > 1000 or hepatitis B virus (HBV) positive. If there was a 
previous deep fungal infection, fungal prophylaxis with voriconazol during minimum 
three months is prescribed. Varicellae seronegative patients shall receive prophylactic 
acyclovir treatment for three weeks following exposure to varicella zoster virus 
(VZV). Anti-pneumococcal prophylaxis is a lifelong preventive treatment for all 
asplenic patients. In case of acute GVHD, fungal and viral prophylaxis shall be given 
if the patient receives a high-dose steroid treatment. In cGVHD, fungal and herpes 
simplex prophylaxis shall be given for as long as the immunosuppressive treatment 
continues. All patients are fully re-vaccinated after HSCT. The revaccination is 
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initiated six months after the procedure. There are no differences in the infectious 
prophylaxis strategy between children and adults (54, 55). 
 
Prophylaxis against CNS relapse: Intrathecal therapy 
At some centres, intrathecal chemotherapy is given during the follow up to prevent 
relapse of malignant disease in the CNS. The data on the efficacy of these invasive 
treatments originate from work by Thompson et al.  in 1986, where intrathecal 
methotrexate after HSCT reduced the risk of CNS relapse in ALL from 19% to 4% 
(56).  Since 1986 the paediatric oncologic treatment has made great progress in 
primary treatment and the conditioning regimens for paediatric HSCT have changed 
and become more efficient. Today the routines and recommendations regarding 
intrathecal chemoprophylaxis to children after HSCT differ among international 
centres (57).  
At our transplantation clinics; CAST and the department for Haematology and 
Oncloogy at the Astrid Lindgren‟s Children‟s Hospital at the Karolinska University 
Hospital Huddinge we had the routine to give six intrathecal injections to patients with 
a high risk of CNS-relapse after HSCT until 2008. The patients considered high risk 
were all ALL patients, AML 4 and 5 and AML M0 –M3 if they had previous 
extramedullary engagement, high presenting leucocyte count or slow response to 
primary treatment. The intrathecal treatment schedule prescribed one injection given 
every two weeks, starting on day + 32 after HSCT. Patients with CNS leukaemia had a 
prolonged treatment regime with intrathecal injections every eight weeks for 18 months 
after HSCT. The prolonged treatment schedules varied in time from patient to patient 
depending on side-effects, other diseases and complications. Intrathecal injections were 
not given if platelet count < 50 x10
9
/L or leukocyte count < 1.0 x10
9
/L. Low platelet 
count, infections or other complications would often delay the start of intrathecal 
therapy, until the second or third month after HSCT. The usual practice for patients was 
to receive cytarabine, but in presence of GVHD methotrexate was used as an 
alternative. The dose was age-dependent: < 1 year of age 16 mg cytarabine or 6mg 
methotrexate, at 1-2 years of age; 20 mg cytarabine or 8 mg methotrexate; at 2-3 years 
of age 26 mg cytarabine or 10 mg methotrexate and over 3 years of age; 30 mg 
cytarabine or 12 mg methotrexate. Despite the delays in starting intrathecal therapy, 
often due to low platelet counts or other complications, patients were generally given 
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their first intrathecal injections within the first three months after HSCT (58, 59). (II, 
III) 
 
 
Complications following HSCT 
The weakened immune system during the first year after HSCT causes a high risk of 
infectious complications of a wide range, which in turn can lead to further 
complications. The donated stems cells ability to react against the patient‟s own cells 
and tissue is called graft versus host disease, GVHD, and is in itself a major risk factor 
for death after HSCT. GVHD can also lead to secondary complications and the chronic 
form of GVHD may disable the patient for years after the transplantation. The 
conditioning and transplantation puts all the organ systems in the body at risk. 
Complications due to HSCT and pharmacological treatment can occur in most organ 
systems of the body. Below, the most common and potentially serious complications 
are described more thoroughly. Other complications, not described in detail here are 
acute respiratory distress syndrome (ARDS), a rare often fatal respiratory condition 
(60) and veno-occlusive disease (VOD, also called sinusoidal obstruction syndrome, 
SOS), a likewise serious condition due to damage of small blood vessels and 
stagnations of the blood flow in the liver (61). In addition there are complications in the 
skeletal system in the form of osteonecrosis (62, 63) in the eyes (64), the kidneys (renal 
failure often due to nefrotoxic drugs) (65) and in the vascular system (thrombosis) (66). 
 
 
Graft versus host disease 
Despite excellent matching with new technologies (high resolution DNA typing) the 
risk for GVHD is 30% in a matched related donor transplantation, and 45% in a MUD 
transplantation in children (8). The GVHD is the reaction of the donors T-lymphocytes 
against the tissues of the patient. The donor T-lymphocytes are highly functioning 
immune cells designed to protect the body from foreign material and – if infused to a 
foreign body- the recipient- they react to the recipient‟s body as they would to a foreign 
tissue or infection (53). The treatment of GVHD is to suppress the already weak 
immune system to avoid the heavy attack on the recipient‟s body. This leads to an even 
higher risk of infections and also to secondary complications from the GVHD drugs. 
High dose steroids- the treatment most commonly used that is very effective, causes 
cushingoid symptoms, gastritis, severe mood changes, increased appetite, reduced bone 
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density and overweight. Long-term treatment with high doses of steroids can also 
reduce height (67) . If the GVHD is severe, a wide range of immunosuppressive drugs 
can be used to incapacitate the T-cell function, with a risk of infectious complications 
and with varying results. As an example it is well known that there is an increased risk 
of CMV infection/reactivation if GVHD is present (68). Acute GVHD (aGVHD) is 
traditionally defined as GVHD appearing within three months (100 days) after HSCT. 
Symptoms still present more than three months after HSCT is chronic GVHD 
(cGVHD). However, in 2005 another categorization was proposed where aGVHD is 
categorized by symptoms and not by the time passed after HSCT and is now standard 
guidelines (69).  
Table 1. 
Classification of GVHD. According to National Institute of Health Consensus 
Development Project 2005 (68). 
 
 
Cathegory 
of GVHD 
 
 
Subcathegory 
Timing of 
symptom 
after HSCT or 
DLI 
 
Presence of 
Acute GVHD 
features 
 
Presence of 
Chronic GVHD 
features 
 
Acute 
 
 
Classic acute 
 
≤ 100 days 
 
Yes 
 
 
No 
 Persistent, 
recurrent or late 
onset 
>100 days Yes No 
 
Chronic 
 
 
Classic Chronic 
 
No time limit 
 
No 
 
Yes 
 Overlap 
syndrome 
No time limit Yes Yes 
 
 
As the severity of aGVHD is an important prognostic factor, accurate clinical staging of 
GVHD is essential. The staging is commonly expressed as grades I-IV (70). Grade I -II 
are mild and moderate aGVHD, grade III is severe and grade IV is life-threatening. 
Involvement of liver or the GI- tract is directly considered as a moderate aGVHD. 
Therefore aGVHD of stage one in the liver and GI, is considered a grade II in severity. 
Skin GVHD is graded depending on the percentage of skin affected and the type of 
rash/erythroderma. Liver GVHD is graded by the degree of bilirubin elevation and 
gastrointestinal (GI) GVHD is graded by the volume of diarrhoea and presence of 
absence of abdominal pain/ileus. Severe aGVHD has a very poor prognosis. In a large 
study from 2002 of CML patients, the patients with aGVHD grade III had a 25% long 
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term survival compared to 63% for the patients with grade I aGVHD (71) . Chronic 
GVHD is one of the major causes of death in children after HSCT. Around 25% of 
paediatric patients develop cGVHD, compared to 30-50% of adult patients (16, 72). 
Chronic GVHD is generally graded as limited or extensive. The cGVHD can affect the 
GI tract, the lungs, the skin, the musculoskeletal system, the liver and the eyes.  Skin is 
the organ most commonly affected. A long-term chronic skin GVHD can cause severe 
psychological strain. The treatment-approach should be multidisciplinary with 
pharmacological treatment of corticosteroids and other immunosuppressive treatments 
such as T-lymphocyte “depletion” (with ATG), extracorporeal photophoresis and 
physiotherapy (16, 53, 72). The cGVHD can manifest itself in the lungs as bronchiolitis 
obliterans (BO) in 8% to above 20% in different studies of HSCT patients (5, 73, 74). 
BO is a fibrous scarring in the bronchioles, which manifests later than three months 
after HSCT and most often with other manifestations of chronic GVHD. Risk factors in 
the recipient are older age and poor lung function before HSCT as well as the choice of 
donor; cord blood has a low risk, and PSCB a higher risk than BM. Recently published 
data suggest that certain genetic and biochemical factors that may predispose patients to 
contract BO (75-77). Respiratory infections in the 110 days following HSCT, also 
increase the risk of BO.  The symptoms of progressing BO may be discrete. Long 
standing cough and dyspnoea with normal chest X ray and spirometry showing new 
onset of airway obstruction are important signs. Correct diagnosis is performed by High 
Resolution Computer Thomography (HRCT) (78). The treatment is, as for other 
symptoms of GVHD, corticosteroids, immunosuppressive therapy and also 
bronchodilators, infectious prophylaxis and sometimes anti-reflux medication. Similar 
pulmonary GVHD manifestations involve the alveolae (diffuse alveolar damage, DAD) 
or take the form of lymphocytic interstitial pneumonia (LIP), bronchiolitis obliterans 
organizing pneumonia (BOOP) or lymphocytic bronchiolitis/bronchitis (77, 79). 
 
Chronic GVHD presenting as symptoms from the CNS are rare. Neuropathological 
findings have shown focal cerebral vasculitis and perivascular lymphocytic 
infiltration/immune-mediated encephalitis in a few published cases (80).There are also 
reports of demyelinating disease of the CNS (81). Among the peripheral neurologic 
manifestations of cGVHD myositis and polymyositis is often listed as these symptoms 
are regarded as neuromuscular in origin. Myositis presents as muscle weakness and 
pain in about 2% of HSCT patients. It is often treatable with corticosteroids and 
methotrexate. Immune mediated neuropathies such as myasthenia gravis and 
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Guillaume-Barré- like symptoms is very rare (occurs in about 1% of patients) (53, 81-
83). Paediatric chronic GVHD survivors have been reported to have a higher risk of 
cataract and also muscle weakness, in long term follow-up (84). 
 
 
The graft versus tumour effect 
The donor T-cells‟ ability to react against recipient tissue does not only result in 
GVHD, but also in a reaction against the patients‟ malignant cells. This is called the 
graft versus tumour or graft versus leukaemia (GVL) effect. Multiple studies have been 
done on how to maximise GVL and minimize GVHD. It is probable that a CD8+cell 
depleted graft would be beneficial, resulting in fewer cases of GVHD with sustained 
GVL and engraftment, but no definite conclusion has been reached. The timing for 
DLIs (donor lymphocyte infusions) after HSCT and blocking or administrating 
different cytokines have also been investigated, but more studies need to be done 
regarding the optimal timing for these interventions (85). The most successful use of 
the GVL-effect with DLI is reported in CML (86) . 
 
 
Infectious complications 
During the first two- four week period after the stem cell infusion, neutropenia 
(neutrophil count < 0.5 x10
(9)
cells/L) increases the risk of infections. The patients are 
therefore placed in isolation. The risk of infectious complications - contagious 
infections from the surrounding environment or reactivation of previously acquired 
latent infections remains elevated during the first six to twelve months or more after the 
HSCT. This is due to the fact that the patient is receiving immunosuppressive drugs and 
the new immune system is under development. It is known that the natural killer cells 
(NK cells) reconstitute within the first 100 days, but that the B- and T- cell function 
only gradually normalises during the first year after HSCT. The factor most important 
for the immune reconstitution is the presence or absence of GVHD and subsequent 
immunosuppressive therapy (16, 82, 87).  
 
A common categorisation of infectious complications after HSCT is: 
 The pre-engraftment period; 0-30 days after HSCT. In this period bacterial and 
fungal infections dominate.  
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 The early post-HSCT period – 30 to 100 days after HSCT. During this period 
aspargillus is a threat, together with cytomegalovirus (CMV) reactivation and 
pneumocystis jiroveci.  
 The late phase - 100 days after HSCT and onwards. In the late period the patient 
is still at risk for CMV reactivation and, especially in the case of GVHD and 
encapsulated bacteria. The patients are also increasingly exposed to community 
acquired infections. 
Infection is one of the most common causes of neurological complications (88) but it is 
also a heavy disease burden for the HSCT patients without neurological complications.  
 
Bacterial infections 
Bacterial infections during the first month after HSCT are most often caused by gram 
positive bacteria; coagulase negative staphylococci (89) coryneibacteriae and alpha 
haemolytic streptococci (90). Infection with gram positive bacteria is associated with 
GI mucosal damage. The gram negative bacterial infections are associated with central 
lines and severe mucosal damage. Among these, E-coli, Klebsiella and Pseudomonas 
dominate (90). The gram negative infections are often severe and associated with high 
morbidity and mortality (90, 91). Bacterial CNS infections are rare (92) . The average 
prevalence of bacteraemia after HSCT is around 40% (91, 93, 94). In chronic GVHD 
patients the opsonization is impaired and the patients are at increased risk of rapidly 
progressive infections with encapsulated bacteria (N Meningitidis, S pneumonia) (95) 
.After the introduction of reduced intensity conditioning (RIC) regimens a reduction in 
severe bacterial infections during the first months (96) was seen in adult RIC patients. 
However, this not been observed in fungal or viral infections (97) . Pathogens with 
antibiotic resistance are among HSCT patients a growing problem, as it is in overall 
health care. A high incidence of resistance has been reported against ciprofloxacin 
which is widely used as bacterial prophylaxis in the neutropenic phase  (89). 
 
Parasitic infections 
Among parasitic infections, pneumocystis jirovecii and toxoplasma gondii are the most 
common infections. These are known common agents also in other immunosuppressed 
patients with T cell defects such as HIV-positive patients. All patients receive 
pneumocystis prophylaxis with cotrimoxasole due to the risk of the highly mortal 
pneumocystis jiroveci  pneumonia. With prophylaxis the risk is significantly reduced, 
from more than 10% to below 1% (98) . Toxoplasmosis encephalitis is the most 
 18 
common manifestation of toxoplasmosis in this group and occurs in a few percent of 
HSCT patients. Toxoplasmosis in HSCT patients has, despite treatment, a very high 
mortality of nearly100%. Often, the diagnosis is not confirmed or found, until after 
death  (99). 
 
Fungal infections 
Risk factors for invasive fungal infections in paediatric patients after HSCT are 
granulocytopenia, indwelling central venous catheters, mucositis and long term high 
dose treatment with corticosteroids (100).Superficial fungal infections are common 
especially due to steroid treatment in both acute and chronic GVHD. Up to 15% of the 
HSCT patients develop systemic fungal infections (35, 90, 100). Aspergillus- and 
candida spieces are the most common systemic fungal agents. Due to fluconazole 
prophylaxis aspergillus has become relatively more common. The invasive fungal 
infections occur in two peaks; one before engraftment and one after three to four 
months (100).Fungal CNS-disease can be caused by Nocardia asteroides which can 
cause brain abscesses, but more commonly, fungal CNS disease manifests as septic 
emboli of aspergillus infections, with a primary infection in the lungs. Aspergillus CNS 
infection is 100 % fatal. The most common cause of fungal meningitis reported in 
immunosuppressed patients, is Cryptococcal neoformans. Most of the cases are HIV-
positive patients, but as Cryptococcus meningitis mainly affects patients with a defect 
T-cell function, HSCT patients are at risk as well. The most common site for 
Cryptococcus infection is though the lungs, followed by the CNS  (101). Zygomycetes 
infection in the CNS results in a vascular invasion leading to thrombosis. The treatment 
is both surgical and pharmacological (with amphotericin B and posaconazole) (101). 
Late fungal infection affects the lungs or sinuses and is caused by aspergillus (95). 
 
Viral infections 
Vigilance and protection against reactivation of herpes viruses is important after HSCT, 
why prophylaxis is given in high risk situations. (see above; Prophylaxis against 
infectious complications). Before transplantation all patients and donors are screened 
for HSV, cytomegalovirus, Epstein –Barr virus (EBV) and VZV.  
 
Herpes simplex virus 
HSV is the herpes virus that reactivates first after HSCT, within a few weeks (102). 
The prevalence of HSV is about 50% in adolescents and increasing with age (103). 
   19 
HSV reactivation in HSCT patients may present as mucositis, oesophagitis, hepatitis, 
pneumonia and encephalitis (102). HSV encephalitis is highly fatal despite aciklovir 
treatment, not only in immunocompromized patients. HSV positive recipients are on 
HSV prophylaxis with aciklovir which has reduced the risk of disease substantially 
(104). In case of CNS HSV infection MRI (magnetic resonance imaging) is 
recommended for imaging to visualise early HSV signs and for an early diagnosis. 
EEG is useful as 90% of the patients present with EEG changes in the early phase 
(101). 
 
Cytomegalovirus 
Reactivation of CMV and EBV are the most feared viral infections. After HSCT, the 
patients are screened continuously with CMV and EBV-PCR, for increased numbers of 
DNA copies of CMV and/or EBV in blood. CMV infection usually occurs early in life 
with a mild fever and rash, or entirely unnoticeable. At least 50% of the adult 
population is seropositive. Severe CMV disease occurs only in immunosuppressed 
patients and can involve the retina, liver, brain, gastrointestinal tract and lungs when 
reactivated after HSCT. CMV reactivation occurs in 30-70% (102) after HSCT if the 
donor/or recipient was CMV-positive prior to transplantation. Despite the high 
prevalence of reactivation, manifest CMV disease is fortunately only seen in 1-6% of 
patients (90). CMV PCR titre is followed every week until three months after HSCT 
and thereafter depending on risk factors for disease. CMV reactivation with a PCR of 
2000 copies/ml shall be treated. This is called pre-emptive therapy, treating the 
reactivation before symptoms manifest themselves. The first choice of therapy is 
intravenous gangciklovir. Due to the potential severity of CMV disease, CMV status is 
a factor in the choice of donor. For the CMV-negative recipient a CMV-negative donor 
is preferred. If the patient is CMV positive a CMV positive donor is preferred (90). 
CMV CNS disease is a late onset disease (median time > 200 days post HSCT). It is 
rare but highly fatal, despite treatment. The afflicted patients have often undergone 
multiple pre-emptive CMV treatments, and gangciklovir resistant CMV is common 
(105).  
 
Epstein-Barr Virus 
EBV is known as the “kissing disease”, often transmitted in adolescens giving the 
patient enlarged cervical lymph nodes and fever. The liver may also be mildly affected 
with elevated liver enzymes. About 60% of 9-12 year old children are seropositive 
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(106). The complication of importance related to EBV in HSCT patients is 
posttransplant lymfoproliferative disease (PTLD), a malignant EBV-driven 
proliferation of lymphoid tissue. EBV is followed by PCR every two weeks the first 
three months following HSCT in patients with increased risk for EBV 
reactivation/infection. The risk factors are: EBV serological mismatch between 
recipient and donor, HLA mismatch- one A, B or DR antigen, cord blood donor, 
lymphoma or congenital immunodeficiency as reason for HSCT (102). If an increasing 
number of EBV DNA copies are detected, a decreased immunosuppression can be 
considered. With further increased titers; rituximab treatment is recommended. 
Rituximab is an antibody towards CD20 positive lymphoid cells. Treatment with this 
antibody has shown a reduction of risk of PTLD (107). Rituximab is also the treatment 
for manifest PTLD disease where not many treatment options are available. EBV 
specific T lymphocytes, or DLI, can be used in life threatening cases (108). PTLD 
occurs in about 1% of HSCT patients and most commonly in the first 6 months after 
HSCT (95). CNS involvement of PTLD is rare but believed to lead to a poorer 
prognosis  (109) . EBV, like CMV, affects the choice of donor. For an EBV-negative 
recipient an EBV-negative donor is chosen if possible. If an EBV-positive donor has to 
be used, T-cell depletion of the donor cells may be considered (110).  
 
Varicellae-Zoster virus 
VZV is the last herpes virus to reactivate after HSCT, at a median of five months after 
HSCT. Reactivation occurs in about 40% of the paediatric patients during the first 5 
year period after HSCT (111, 112). Limited dermatomal zoster is the clinical 
presentation in the majority of cases, and disseminated cutaneous involvement in 20%.  
Visceral involvement is seen in 5-10% (113, 114).VZV can also cause meningitis, 
meningoencephalitis, myelitis and Guillaume Barrée, as well as paralysis of brain 
nerves.  CNS involvement is feared but rare (< 1% of VZV cases). Aciklovir is a well 
known treatment which in severe cases can be combined with foscarnet (101, 115-117). 
Post-herpetic neuralgia after the acute infection is common in adults but less frequent in 
children (112). 
 
Human herpes virus 6 
Another herpes viruses with importance in the HSCT setting is human herpes virus 6 
(HHV-6). Primary infection with HHV-6 occurs in early childhood, presenting to the 
paediatrician as the familiar clinical picture of exantema subitum.  Above 75% of the 6-
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year olds are HHV-6 positive (118). As CMV and EBV, the HHV-6 stays latent in the 
body and may be reactivated during immunosuppression (119). Risk factors for 
reactivation are CB donors, an HLA mismatch between donor and recipient, as well as 
low anti-HHV-6 IgG titer in the recipient before HSCT. Reactivation of HHV-6 occurs 
early after HSCT (approximately after 3-4 weeks) and is believed to cause delayed 
engraftment and is associated to increased mortality (120). HHV-6 is the most common 
cause of encephalitis in HSCT patients. It has an early onset, within 100 days after 
HSCT, and high mortality (101).The treatment used is foscarnet or ganciklovir (17, 
119, 121). 
 
Polyomavirus 
Polyomavirus (PyV) are neurotropic viruses and more specifically, human PyV 
(HPyV) are known to cause neurological complications in the immunosuppressed 
patient (122-127). Primary infection by the two first discovered HPyV, BKPyV and 
JCPyV (128, 129)  give mild respiratory illness or no symptoms in immunocompetent 
individuals (130). Primary infection is followed by a lifelong latency in the kidneys but 
also in B-lymphocytes (131)  and in the case of JCPyV, in the brain (132). The mean 
seroprevalence for BKPyV and JCPyV together is around 60% in people aged 60 or 
older. Reactivation of BKPyV is frequently observed in the context of HSCT and renal 
transplantation, both in urine and serum. In some allogenic HSCT patients BKPyV can 
induce haemhorragic cystitis (HC) (133) while in some renal transplant patients it can 
cause BKPyV-associated nephropathy  (134). Reactivation of JCPyV in the urine is 
often seen in healthy individuals. In the context of immunosupression, such as HIV-
infection, patients with lymphoproliferative disease, during transplantation or 
chemotherapy as well as in immunodeficiencies JCPyV can cause progressive 
multifocal leukoencephalopathy (124, 126). There are also a few reports of CNS 
disease due to BKPyV (122, 123, 125, 127) . KIPyV, WUPyV and MCPyV (Merkel 
cell PyV) are more recently discovered HPyV and data on whether these viruses are 
capable of infecting the CNS are scarce. So far their presence has not been identified in 
childhood brain tumours (135). However, in one study published in 2009, WUPyV was 
suggested to be linked to PML in a patient with HIV (136). KI- and WUPyV were 
originally found in nasopharyngeal aspirates (137, 138) and MCPyV in Merkel cell 
carcinoma (MCC) (139). The seroprevalence of KI and WUPyV is reported to be high 
already in childhood (140, 141) . Existing data suggests a mild initial infectious event 
upon primary infection, which is mediated by respiratory or faecal-oral transmission 
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during childhood (141). The presence of KI-, WU- and MCPyV has been studied in the 
respiratory tract, blood and lymphoid tissue of immunocompromised individuals, and 
to a lesser extent in their urine, CSF and faeces. Generally they are found more often in 
these patients than in healthy controls (142-147).  In 2010 and in February 2011 
discoveries of four new human PyV were published. These viruses; PyV 6, 7, 9 och 
TSV PyV were found exclusively on skin. Weather these viruses are of any importance 
for HSCT patients is yet unknown, but as they belong to the PyV family, neurotropic 
abilities and importance for immunocompromized patients must be studied in the 
coming years (148-150) . 
 
Other viral infections 
Viral contagious infections of importance are respiratory syncytial (RSV) -, adeno-, 
entero-, rhino-, parainfluensa B, metapneumonovirus and gastroenteritis - viruses.   
 
More attention than previously has been given to the risk of adenoviral infection after 
HSCT as the infection becomes more common due to potent immunosuppressive 
therapy and the use of T cell depletion (151, 152) . Adenovirus infection in the 
immunocompetent host is most often a harmless upper respiratory tract infection, or a 
GI-infection. However, disseminated untreated adenovirus infection in 
immunosupressed patients has a mortality of 60% (151-153). Adenoviral 
meningoencephalitis is reported after HSCT in children (154). Generally, adenoviruses 
infect children between 6 months and 5 years of age, why paediatric HSCT patients are 
at high risk.  During the last ten years, cidofovir has emerged as an effective treatment 
(155, 156). 
 
Parvovirus is another “paediatric virus”- where the subtype B19 is known as the cause 
of exantema infectiosum or “fifth disease”. Parvovirus infects mainly school-aged 
children and young adults, during seasonal “outbreaks”. In elderly people, over 85% 
are parvovirus seropositivity  (157). The virus can in patients with underlying 
haematological disorders, cause bone marrow depression and sudden onset of severe 
anemia (pure red cell aplasia)  (158, 159). In HSCT – medicine the virus can be the 
cause of unexpected decrease in bone marrow function and/or slowed haematological 
recovery after the transplantation (160).  
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Respiratory syncytial virus is a seasonal respiratory infection, widespread in all 
children under 6 years of age. The infection can be severe for younger and premature 
children, but presents as a mild upper respiratory tract infection in most children. In 
HSCT patients up to 35% have been found infected. A RSV-lower respiratory tract 
infection can be life threatening. RSV has been shown to increase the mortality risk 
after HSCT by 60%. Ribavirin, orally or intravenously is the treatment at hand, 
although it is not always effective (161). 
 
The recent epidemic of H1N1 influenza reached the HSCT-wards. H1N1 in HSCT 
patients presented with fever and respiratory symptoms. A third of the patients 
developed pneumonia and treatment in Intensive Care Units (ICU) was common 
(15%). The mortality is around 20% (162-165). Ozeltamavir is the treatment of choice 
and appears to decrease mortality if initiated early in the disease process. Seasonal 
influenza/Influenza B affects about 1% of the HSCT population. Parainfluensa viruses 
also contribute to morbidity and mortality after HSCT, although to a lower extent than 
RSV. 
 
Looking specifically at CNS infections, toxoplasma and fungal infections are the most 
common CNS infections in patients with malignancies. The risk of CNS infections in 
the HSCT group is highest in the first three months after HSCT. Regarding viral 
infections; in a study of 2,628 patients, 32 had viral encephalitis (1.2%) and the most 
common agents were HHV-6, EBV, HSV, JCPyV and CMV, VZV as well as 
adenovirus. Bacterial CNS infections are most often caused by staphylococci-, gram 
negative bacteria or Listeria monocytogenes and later in time after HSCT; 
Cryptococcus. CNS infections affect around 2% of HSCT patients (92, 101) 
 
 
Relapse after HSCT 
Malignant relapse after HSCT is naturally the most feared outcome. Although, HSCT is 
not today, as earlier, the very last treatment to offer a patient with relapsing malignant 
disease. DLI can be given in an attempt to induce GVT effect. A second and even a 
third HSCT is sometimes done (58, 86). The outcome after HSCT has improved 
substantially over time, and thus the relapse risk has decreased. In the 1970‟s the 
relapse risk for ALL after HSCT was over 40% (166). Gooley et al reports that the risk 
of relapse or progression to malignant disease decreased by 21% comparing patients (of 
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all ages and mixed diagnoses) transplanted 1993-1997 to patients transplanted 2003-
2007 (9). The relapse risk after HSCT for haematological malignancies is now around 
30% in children (18, 167). The risk differs depending on leukaemia type and risk 
group. For children with a positive MRD before transplantation the prognosis is poor; a 
50% risk of relapse and death within one year has been seen in this group (168). Most 
common are relapses in BM only; about 60% of relapses (169, 170). About 20% are 
combined extramedullary and BM relapses and 20% isolated extramedullary relapses. 
The most common sites for isolated extramedullary relapses are testes, cns, skin and the 
head and neck area. Relapse is rarely seen in lymph nodes, bones, kidneys or breast 
(171, 172).  
 
The incidence of isolated CNS relapse after HSCT is difficult to estimate, as there are 
only a few published studies, which have all been done on small patient groups. Two 
studies published in the eighties (56, 173) reported that the overall risk of isolated CNS 
relapse for ALL patients after HSCT was between 11% and 13%. In patients with 
previous leukemic CNS involvement the risk was significantly higher (>25%) than in 
patients with no previous CNS involvement (5–7%) (56, 173, 174). A more recent 
larger study on CNS relapse after HSCT of adult HSCT patients with ALL and AML 
showed a 3.2% prevalence of relapse in the CNS relapse combined with other relapse 
after HSCT.  ALL patients, patients with prior CNS-leukemia, patients with active 
disease at HSCT had an increased risk for combined CNS relapse. The risk of 
combined CNS relapse if the patient had prior CNS involvement of leukaemia was 
21.3% and the risk without was 1.3%.  Interestingly chemoprophylaxis against CNS 
relapse after HSCT was also a risk factor for combined CNS relapse. Isolated CNS 
relapse was seen in 0.9% of patients. In these patients ALL as diagnosis, the absence of 
HLA mismatch, use of CB or PCSB, prior CNS disease and intrathecal 
chemoprophylaxis after HSCT increased the risk for isolated CNS relapse (175).  
 
To reduce the risk of CNS relapse of leukaemia, intrathecal chemotherapy is given after 
HSCT. The efficacy of intrathecal chemotherapy against CNS relapses has proven to be 
very effective in primary leukemia treatment. When introduced in the 1970s‟, it 
reduced the CNS relapse frequency with 50%, from 50% to 23% (176). Thompson et 
al. completed in 1986 the only study to clearly compare regimens with or without 
intrathecal methotrexate after HSCT (56). Treatment with intrathecal methotrexate had 
a protective effect against CNS relapse in ALL patients after HSCT. The effect was 
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particularly strong in patients with previous CNS disease. There was no demonstrable 
effect of intrathecal methotrexate on CNS relapse in AML. The effect of intrathecal 
therapy on CNS relapse has not been confirmed in other larger studies and the 
intrathecal treatment itself has been associated with many neurological complications 
(173, 175, 177-179). Thompson et al and Oshima K 2008 noted in their studies a higher 
risk for leucoencephalopathy in the intrathecally-treated patients (56, 175). In a small 
study of six patients, symptoms ranging from mild headache to sacral radiopathy with 
irreversible cauda equina syndrome was seen in one patient and progression of a pre-
existing leucoencephalopathy in another after intrathecal chemotherapy. The two 
patients with the most severe complications did have a previously known CNS 
diagnosis, a prior subarachnoidal haemorrhage and leucoencephalopathy respectively 
(180). Intrathecal cytarabine has proven to be safe without major complications in other 
studies (181, 182).  
 
The treatment for CNS relapse after HSCT is individual depending on diagnosis and 
prior CNS treatment burden. The treatment often includes intrathecal chemotherapy, 
DLI and sometimes a third HSCT. The numbers are small and outcome differs between 
the case reports and studies published. The outcome was reported a “surprisingly good” 
in the study of Oshima K from 2008 with three patients out of seven with isolated CNS 
relapses who were alive and leukaemia free for over a year after CNS relapse (175).  
 
 
Secondary malignancies 
The data concerning secondary malignancies (post transplant malignancies, PTM) after 
HSCT  is accumulating as follow up time increases with prolonged survival. Risk 
factors for PTM are previous radiotherapy, chemotherapy (especially alkylating agents) 
and cGVHD (16). Post-transplant MDS and AML are associated with the carcinogenic 
effect of previous chemotherapy. Several studies have shown that the risk of PTM is 
increased 5 times (all cancers) and 2- 3 times for solid tumours which gives a 
cumulative risk of about 3% after HSCT in children (95, 183-185) The risk seems to be 
inversely correlated to the age of the patient at HSCT (186, 187).The PTM can be 
divided in two major groups; haematological; AML/MDS diagnoses generally 
occurring during the first decade after HSCT (183).The main solid tumours seen are 
skin-cancer, oropharyngeal cancer, thyroid-, and breast- cancer  (16).The risk is 
especially high for brain/CNS and thyroid cancer in young children. The appearance of 
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these tumours was often preceded by treatment with CNS irradiation (186, 188). The 
PTLD is a third group of malignant disease after HSCT, this was described previously 
under infectious complications, as it is an EBV driven disease.  Survival after a solid 
secondary tumour and it‟s treatment is about 60% after 5 years (189).The survival after 
treatment related AML (t-AML)/MDS is poor with a median survival of 6-12 months 
(190). 
 
Endocrine complications  
The treatment included in the HSCT procedure can affect endocrine function in several 
ways. The previously frequently given single dose of TBI was associated with a higher 
risk than the present fractioned TBI- regimens (191, 192). A great concern for the 
patients is the almost 100% risk of gonadal dysfunction and infertility after HSCT. The 
risk is higher for women than men, and higher with busulphan- and TBI- containing 
regimens than with Cy alone. If HSCT is done before puberty the chance of restored 
gonadal function is better.  Few men need hormone replacement therapy (HRT) while 
most females will require HRT both to induce puberty, to maintain menstrual cycles 
and to support bone mineralization/turnover. In the group of children with malignant 
diseases who are aggressively treated, fertility is as low as 3% in women and, at most, 
20% in men. The option of freezing ovarian tissue prior to HSCT is developing and for 
men cryopreservation of sperm is a well known option which can increase the chance 
of conceiving biologically after HSCT (87). Growth failure is another common 
complication however it is likely of multifactorial origin. Younger age at HSCT, TBI 
and cranial radiation results in higher risk for growth retardation (95). The growth 
retardation seen is generally about -1 standard deviation (SD) in height compared to 
expected height without HSCT. One of the most common late HSCT complications is 
hypothyroidism (87). Patients treated with TBI are most at risk, with a 15% risk of 
TBI-related hypothyroidism, if fractioned TBI has been given. With single dose TBI, 
which was used earlier, the risk was as high as 50%. A busulphan/cyclophosphamide 
conditioning reduces the risk to 11% (95). 
 
 
Neurological complications 
The neurological complications seen within the first months after HSCT are related to 
the pancytopenic-state (infections due to neutropenia, bleedings due to 
thrombocytopenia) and to neurotoxic effects of some of the drugs given. Later the 
   27 
sequelae from CNS infections and the irradiation damage to the central nervous system 
become apparent, often in the form of decreased cognitive functions. In an overview of 
available studies on neurological complications after HSCT in children (Table 1) we 
see that the most common CNS symptoms are seizures, followed by altered 
consciousness and headache. The underlying causes, excluding relapse of malignant 
disease in CNS, are infections, drug toxicity (cyklosporin causing most complications), 
cerebro vascular disease (CVD) and metabolic encephalopathy. There are also a 
number of incidences where the underlying cause is unknown. Peripheral neurological 
complications are rarely reported. Polymyositis/myopathy related to GVHD is, 
although rare, the one most commonly described. Only one study reports a high 
incidence (14 %) of peripheral neurological symptoms, where infections caused several 
cases of cranial nerve palsy (174)  (Table 1). 
 
Six of the studies examining risk factors generally agree on an increased risk for 
neurological complications in transplantations where an unrelated donor is used, 
cyklosporin is used as GVHD prophylaxis  or where the recipient suffers from GVHD 
> gr 2 (Table 1). In other studies the risk of neurological complications after HSCT is 
shown to increase when both CNS irradiation and intrathecal therapy is given before 
HSCT (56). It is probable that intrathecal therapy given after HSCT adds to that risk. 
Five of the listed studies confirm the increased mortality risk for patients having 
suffered from neurological complications (Table 1). 
 
Drug-induced neurotoxicity is one of the major causes of neurological complications 
after HSCT. Busulfan, cytarabine and etoposide are drugs given in the conditioning 
treatment that can cause seizures, encephalopathy and confusion.  Ciklosporin – very 
commonly used as GVHD prophylaxis- can cause neurologic toxicity in up to 28% of 
recipients (193). Some of the antibiotics and other supportive drugs used can also cause 
complications involving the CNS; high dose corticosteroids are known to cause severe 
mood swings, cephalosporins can cause seizures, while there‟s a risk of developing 
parkinsonism and in rare cases progressive leukoencephalopaty, with the anti-fungal 
drug amphotericin B (194).The drug related complications are most often immediately 
reversible with reduction of the drug dose. However, the myopathy which can be seen 
as a peripheral neurological/muscular complication from high doses of steroids, can 
take months to reverse after cessation of steroids. 
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Cerebrovascular disease after HSCT includes cerebral haemhorrages, thrombosis and 
vasculitis. Among cerebral haemhorrages, intrachranial and subarachnoidal 
haemhorrages are most common, as well as associated with the worst prognosis(195, 
196). Factors increasing the risk of intrachranial haemhorrage (ICH) are systemic 
infection, low platelets, GVHD and VOD.  Known vascular risk factors as high blood 
pressure, diabetes mellitus and thrombocytopenia contribute to the risk of 
cerebrovascular disease after HSCT. Subdural haemhorrages occur less frequently after 
HSCT (88, 196, 197). 
 
 Infection is the third of the major causes, responsible for up to 25% of neurological 
complications after HSCT (15, 18, 174). CNS infections are though rather rare. Viral 
encephalitis, with a median onset time of three months after HSCT, occur in about 1% 
of patients with a 1-yr survival of 55%  (101). Late CNS infections occur in about 7% 
of the patients and foremost in the patients on continuous treatment with 
immunosuppressive cGVHD treatment. See above; Infectious complications.  
 
Metabolic disturbances involving the CNS, often called metabolic encephalitis, may 
be caused by renal failure, electrolyte imbalance, hypoxia or infections (119). One 
large study of 405 paediatric patients found that 6.4% of the patients had 
encephalopathy after HSCT (198). The incidence is though difficult to assess, due to 
the poor characterisation of this diagnosis. The EEG changes are most often a diffuse 
slowing of the EEG pattern, on MRI cerebral atrophy and focal lesions can be seen. 
In over half of the encephalopathy patients in the above mentioned study, there were 
leukoencephalopathy changes visible on the MRI. Often no distinct cause is found. In 
these patients, a combination of many risk factors may be responsible. 
 
Leucoencephalopathy is a feared complication most commonly seen in heavily CNS-
treated patients. CNS irradiation and intrathecal chemotherapy combined, results in a 
high risk of leucoencephalopathy. Thompson et al found in 1986 a prevalence of 7 % of 
leucoencephalopaty in a group of patients that received CNS-therapy both before and 
after HSCT. Leucoencephalopathy was not seen in any of the patients who only had 
CNS-therapy prior to, or after HSCT. In a study from 2007, six of 138 paediatric HSCT 
patients developed leucoencephalopaty and two of the six patients died during follow-
up.  The cause of leucoencephalopaty is unkown, but all patients in this study were 
receiving cyklosporin, which can be a contributing factor. JCPyV is believed to be one 
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of the causative agents involved in the development of leucoencephalopathy, which has 
been described earlier (132). 
 
Posterior reversible encephalopathy syndrome (PRES) is a syndrome defined by 
clinical and radiological findings. These include headache, altered consciousness, 
visual disturbances, seizures and predominantly subcortical white matter imaging 
changes, posteriorly or in the parieto-occipital area. The changes can also include grey 
matter areas. The radiological findings are bilateral, showing low attenuation of the 
posterior and occipital lobes on CT scans. On magnetic resonance imaging (MRI) they 
are pathognomonic with hyperintensity in T 2 weighted images and typical lesions on 
FLAIR (fluid attenuation inversion recovery) images. PRES can be described as 
cerebral oedema and microinfactions, caused by hypertension (more commonly in 
adults than in children) or renal insufficiency together with chemotherapy and/or 
immunosuppression and other not yet described factors. PRES is despite its name not 
always reversible. Immediate treatment including withdrawal of suspected causative 
agents, aggressive blood pressure treatment and anticonvulsants is essential to avoid 
progression and death. PRES has been reported in 56 paediatric patients undergoing 
cancer treatment (199) but PRES is likely to be the true diagnose in many patients 
where the neurological complications after HSCT are diagnosed as “seizures of 
unknown cause” or “encephalopathy” without further specification. The diagnosis was 
first recognised in 1996, after the introduction of MRI into wider clinical practice. 
 
Long-term neurological consequences are not sufficiently studied. In Clarke 2010, a 
long-term follow up study of paediatric patients after HSCT the only long-term 
neurological sequelae listed were visual disturbances (200). The same study showed 
lower health related quality of life (QOL) score compared to non-transplanted 
paediatric cancer survivors. A Swedish study from 2005 did on the contrary not see a 
lower QOL score in HSCT patients compared to the norm (201). That study revealed 
though that the HSCT survivors had a higher risk of pain related problems. Long-
term impact on parameters as IQ, achievement, memory and fine motor functioning 
are seen in some studies (202) especially in patients with previous cranial irradiation, 
TBI and in those patients who were very young at the time of CNS-directed treatment 
(13, 14, 203, 204). There is data supporting a decline of cognitive function after 
HSCT in patients that have received CNS irradiation. Patients who have not 
undergone CNS irradiation may have a decline in cognitive functioning at one year 
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after HSCT, but functioning has often improved at three year follow up controls 
(205).  
 
Late peripheral neurological complications are not common. Polyneuropathy of 
Guillaume-Barré type as well as chronic demylenating polyneuropaty are considered to 
be caused by GVHD and/or the neurotoxic effect of calcineurin inhibitors and other 
drugs. Pain and muscle weakness is more common in HSCT long-term survivors than 
others (64, 200). Polyneuropathy causing weakness, muscle spasm, muscle cramps and 
similar peripheral symptoms are a manifestation of cGVHD (81). 
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AIMS OF THE THESIS  
 
The overall aim of the thesis was to identify neurological complications after paediatric 
HSCT and their possible causes and thereby, in the future prevent this type of 
complications by different interventions.  
 
Paper I: To study the incidence of, and contributing factors to acute neurological 
complications after HSCT in children.  
Paper II: To study effect and complications of intrathecal chemoprophylaxis against 
isolated CNS relapse of leukaemia in children after HSCT. 
Paper III: To study effect and complications of intrathecal chemoprophylaxis against 
isolated CNS relapse of leukaemia in children after HSCT with a larger material than in 
the previous study, in order to form recommendations regarding intrathecal 
chemoprophylaxis.  
Paper IV: To study whether BK-, JC-, KI-, WU and MCPyV DNA was detectable in 
CSF from immunocompromised patients with neurological complications after HSCT 
in order to learn more about the fairly newly discovered polyomaviruses KI-, WU and 
MC and their role after HSCT. We also wanted to find out whether some of the 
unexplained neurological complications after HSCT can be explained by polyomavirus 
reactivation/infection in the CNS. 
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PATIENTS, MATERIAL AND METHODS  
 
PATIENTS AND MATERIAL 
 
Patients and material, Paper I 
One hundred and forty four paediatric (< 18 yrs of age) patients who underwent HSCT 
at the Karolinska University hospital (Huddinge) between 1995 and 2002 were 
included in the study.  The patient material reflected the mixed group of patients who 
are eligible for paediatric HSCT with varying preceding treatments, donor types, 
conditioning regimen and background disorders (malignant; 108 patients, and benign; 
36 patients). Age-median was 8.9 years.  The background factors studied were: age at 
transplantation, sex, pre-HSCT herpes virus serologies for CMV, EBV, HSV, VZV, 
transplantation related diagnosis and it‟s treatment, other diagnoses, previous 
neurological diagnosis/symptom, previous treatment for epilepsy and exposure to pre-
HSCT irradiation. The transplant related factors registered were: conditioning regimen 
and whether this included TBI and/or etoposide, type of donor, type of GVHD 
prophylaxis (methotrexate or not) and presence of GVHD.  In the search for factors 
contributing to neurological complications blood pressure level, the level of creatinine, 
haemoglobin, bilirubin, platelets, leukocytes and electrolytes (potassium, sodium, 
magnesium, calcium) at admittance and the number of aberrant (high or low, compared 
to age-adjusted reference values) values of these parameters throughout the study 
period, the first three months period after HSCT  were registered. The number of 
ciklosporin concentrations > 250 ng/L throughout the three months period and weight 
at admittance and lowest and highest weight during the three months period were also 
registered. If a neurological complication occurred the symptoms and the results of all 
investigations done to determine the cause (EEG, neuroradiology, blood and CSF 
cultures) the vital parameters and the laboratory results on the day of the complication 
were registered. Death and cause of death and study time for each patient were also 
registered. The data was collected from original paper- and computerized patient chart 
as well as microfilms in a de-identified database.  
 
Patients and material, Paper II and III 
A total of 120 paediatric HSCT patients transplanted either at the Karolinska 
University Hospital or Uppsala Academic Children‟s Hospital between 1992 and 
2005 were included in the study for paper II. Eligible for intrathecal 
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chemoprophylaxis and therefore for inclusion in the study, regardless of whether they 
had received intrathecal prophylaxis or not, were all ALL patients, all AML M4 and 
AML M5 patients as well as the AML patients with AML M0-M3 with high risk 
factors such as a very high presenting leukocyte count or another high risk factor such 
as extra-medullar involvement or slow response to primary treatment. Patients who 
died or relapsed with malignant disease before three months had passed after HSCT 
were excluded since the effect of the intrathecal treatment could be evaluated three 
months after HSCT, the earliest. In Paper III the study was enlarged to include 
patients transplanted between 1992 and 2006. The patients‟ charts from Study II were 
re-reviewed as new parameters were included (specification high risk factors for ALL 
and AML) in study III and patients from the two remaining Swedish paediatric HSCT 
centres in Gothenburg and Lund were added as well as patients transplanted during 
the same period in Helsinki, Finland and Utrecht in The Netherlands. In total 397 
patients were included. The data was collected from original paper- computerized 
patient charts and microfilm. Information about background factors, disease and 
HSCT procedure was recorded (see above, Paper I regarding the background and 
transplantation related parameters recorded) as well as outcome parameters such as 
relapse, type of relapse, time of relapse, neurological complications and death. The 
information collected regarding intrathecal chemotherapy was; the number of both 
pre- and post HSCT intrathecal chemotherapy injections, type of drug given in the 
post-HSCT injections, and at what day after HSCT the intrathecal therapy was 
started. All data was collected in a de-identified database. Data regarding HSCT 
complications with focus on neurological and cognitive complications, relapse in the 
CNS, relapse of any type and death after HSCT was also collected. Information from 
Gothenburg, Lund, Uppsala and the Helsinki and Utrecht centres were collected at the 
respective site by the co-authors on site after which it was gathered and analyzed in 
Stockholm.  
 
The standard intrathecal treatment was six injections starting one month post HSCT 
and then given every two weeks. Patients with previous CNS leukaemia had a 
prolonged treatment regimen of 18 months where intrathecal injections were given 
every eight weeks. The drugs used were most commonly cytarabine and 
methotrexate. Cytarabine was most often used as the standard intrathecal drug but in 
patients presenting with GVHD, methotrexate was preferred. For some patients with 
an individual sensitivity to, or side-effects from cytarabine, methotrexate was used 
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and vice versa. This resulted in a mixed treatment course where both drugs were 
given in 23% of the patients in Paper II and 30% of the patients in Paper III. The 
average number of intrathecal injections was six in both studies and all of the patients 
with any kind of post-HSCT intrathecal regimen were analyzed together as one 
group, the “intrathecal group”.  
 
Patients and material, Paper IV 
To retrospectively analyze the presence of polyomavirus DNA in immunosuppressed 
patients with neurological complications during the first year after HSCT, CSF samples 
from patients transplanted between the years 2000-2008 was collected form storage at 
the Department for Virology, Clinical Microbiology, Karolinska University Hospital 
Huddinge. During the study period 598 patients had undergone 635 allogeneic 
haematopoietic stem cell transplantations at the Centre for Allogeneic Stem Cell 
Transplantation (CAST), Karolinska University Hospital Huddinge. CSF was available 
in sufficient amount for analyses from 20 of 46 patients where a lumbar puncture (LP) 
had been performed, and viral analyses ordered during the first year post HSCT. A bio-
bank was set up for storage of the selected samples according to the rules of the 
Karolinska Institute and the Karolinska University Hospital. The LP‟s had been 
performed between five and 313 days post HSCT (median time 68 days). The CSF was 
in the clinical setting immediately analyzed depending on clinical suspicion and 
thereafter the leftover CSF was stored at -20 
0
C. The 20 patients in whom we were able 
to perform analysis were of all ages (1 to 60 years old, mean 31 years old) with five 
children < 18 in the group. Seventeen were transplanted due to a malignant disease and 
the remaining three were transplanted due to sickle cell disease, thalassemia and FHL. 
Six patients received a reduced conditioning regimen. Data regarding the diagnosis, 
conditioning, neurological symptoms and the outcome for these patients was collected 
from computerized charts and registered in a de-identified database together with the 
results of the virological analyses. 
 
 
METHODS 
All the studies had a retrospective approach; hence background data as well as data 
concerning risk factors and outcome were collected retrospectively from patients‟ 
charts. Data were registered in Exel ® files.  Statistics were computed with the 
statistical software Statistica ®. The level of statistical significance was set at p< 0,05 
in all studies.  
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Methods, Paper I 
In Paper I background factors, the treatment of and the outcome for patients with acute 
neurological complications occurring within the first three months after HSCT (n=19) 
were compared with the same parameters for patients without neurological 
complications in the first three months (n=125). Blood pressure, electrolytes, 
ciklosporin concentration levels, creatinine and bilirubin levels were collected from 
daily/weekly registrations for all patients for the first three months after HSCT. Blood 
pressure, and creatinine above standard age-adjusted reference values was registered as 
high, for ciklosporin > 250 ng/L was registered as high and electrolytes were registered 
as “high” or “low” depending on their accordance with standard reference values.  
Bilirubin was “high” if above 20 µmlol/L of bilirubin. Haemoglobin was registered as 
low below 80 g/L, platelets < 20 x 10(9) /L and low leukocytes was defined as poly < 
0.5x10(9)/L. The patients‟ baseline viral serology status on herpes viruses; CMV, EBV, 
HSV and VZV, which are routinely registered in HSCT-care were also documented 
and analysed as potential risk factors. The neurological complications were categorized 
as belonging to either of the following groups of symptoms; altered consciousness, 
seizures, headache/nuchal rigidity or paresis and to belong to one of the following 
diagnosis groups; encephalopathy, seizure, infection, meningitis or CVD.  The follow 
up period was from transplantation to death or lost to follow-up four years (mean). 
Statistical analyses were performed with the chi-squared test, and if the numbers were 
small, with Fischers‟ exact test. We used the Wiklcoxon matched pairs test in order to 
analyze the aberrations in laboratory parameters before and after the neurological 
complication. The Mann Whitney U test was applied to compare the number of positive 
herpes virualserologies in donors and recipients in the two groups, i.e. the group with 
neurological complications and the group without. A logistic regression model was 
applied to analyze the risk for a neurological complication considering the serological 
status of CMV and HSV infection, in the recipient and donor respectively. A Kaplan 
Meier survival analysis was performed. 
 
Methods, Paper II and III 
In Paper II and III the outcome for patients receiving intrathecal chemoprophylaxis post 
HSCT, was compared to patients who did not receive this treatment. In paper II there 
were 74 patients receiving intratheal therapy vs 46 patients not given intrathecal 
therapy and in paper III; 136 vs 261 respectively. In both studies there were a 
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difference, (although not statistically significant in Study II) in the background data 
between the proportion of children who had received pre-HSCT CNS irradiation with a 
larger proportion in the group treated with intrathecal therapy. The groups were 
comparable in all other aspects considered. The primary end-point was isolated CNS 
relapse, but also mortality and relapse overall as well as parameters to detect 
neurological complications secondary to the intrathecal treatment were registered and 
analysed. A neurological complication was defined as one of the following conditions: 
seizures, cerebrovascular disease, peripheral neuropathy, altered consciousness, visual 
disturbances, serious/repeated headaches or cognitive difficulties. These were then 
classified as either cognitive or non-cognitive in nature. Two additional parameters 
were collected as measures of estimated cognitive function in the patients; the grade the 
in school the patient was in, in relation to his/her age and an activities of daily living –
score (ADL-score) at one year after HSCT and repeated at the end of follow up. For the 
ADL –score the Lansky performance scale was used for the patients < 16 years of age 
and the Karnofsky performance score was used for patients > 16 years of age (206, 
207) . The study period for Paper II was 1
st
 of January 1992 to June 30
th
 2007 (mean 
follow-up time four years) and for Paper III 1
st
 of January 1992 to 31 aug 2008 (mean 
follow-up time 4,2 years).   
Statistical considerations: The study would require 1500 subjects per group to detect a 
difference of 1% in CNS relapse after HSCT between the groups, as the outcome is 
very rare. It is estimated to be 2-5% without previous CNS involvement and 11-27% 
with prior CNS involvement. However, the study size was determined by the number 
of patients who were available for inclusion. With 397 patients included in study III, 
the power of the results to detect an absolute difference in outcome of 5%, between the 
groups studied, is 80%. Study II had a yet more insufficient number but was done, with 
this in mind, as a pilot study with available patients at the two participating centres. 
 
Methods, Paper IV 
The CSF samples of the 20 patients were analysed for the presence of PyV DNA. Data 
regarding background factors, disease, conditioning treatment, GVHD prophylaxis and 
clinically diagnosed PyV infections were collected from patients‟ charts and registered 
in a data base. The registry also included other data on other viral infections and their 
treatment as well as data regarding the neurological symptoms at the time of LP and 
data on the outcome of the HSCT.  
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The BK- and JCPyV were analysed with a nested PCR which detects both BK- and 
JCPyV. This PCR can detect approximately 10 genomic copies of BKPyV plasmid 
DNA and 5-10 copies plasmid JCPyV DNA (208-210). The CSFs (10 µl) were heated 
at 94°C for 9 min for denaturation before added to the PCR mix as previously done by 
Bogdanovic et al (210). The KI and WU PyV were also analysed with a PCR which 
detects both viruses. This PCR can detect around 10 copies of a KI PyV VP1 gene 
containing plasmid (133). Similarly, the CSFs (4 µl) were heated at 94°C for 9 min for 
denaturation before added to the PCR mix (210).The MCPyV was analysed with a new 
PCR assay. The 4 µl CSF sample had a 9 min denaturation period and was then added 
to the PCR mix for 40 cycles of 30 sec at 95°C, 30 sec at 53°C and 45 sec at 72 °C. 
DNA from a MCPyV positive MCC was used as positive control. The primers, 137-
MCPyV573.F and 138-MCPyV739.R generating an amplicon of 177 bp from the early 
part of LT: 137-MCPyV573.F; GTCTCGCCAGCATTGTAGTCT and 138-
MCPyV739.R; GCAGTAAGCAGTAGTCAGTTTC. This PCR assay had a detection 
limit of 10 MVPyV genomes. 
 
 
ETHICAL PERMISSIONS AND CONSIDERATIONS 
The research group has had the standpoint that information about new studies and 
especially those who might question treatment already given might cause distress to 
patients who have already undergone a difficult treatment and especially cause distress 
in those families where the patient has deceased. This has to be weighed against the 
individual patient‟s right to privacy and the right to decide whether his/her hospital 
charts may be scrutinized for research. We applied therefore in a similar manner to the 
Board of Ethical permissions concerning the patient information and consent regarding 
all the four studies. In Paper I and II we were excused from asking families of deceased 
patients, and patients of unknown fate and of current address living abroad, about 
participation.  The willingness to participate in the studies among the patients asked 
about participation was high; 144/147 and 120/122 respectively. Study III was an 
extension of study II and on the basis of the results from Paper II, study III was 
regarded as a follow up study of clinical results and no extra consents needed to be 
sought from the patients of the children transplanted in Stockholm or Uppsala. For the 
children transplanted in Gothenburg, Malmö, Utrecht and Helsinki a general consents 
for participation in research studies were standard routine at each of these centres. In 
study IV ethical permission for the study did not dictate that information about or 
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consent for the study had to be communicated to/attained from the participants. In 
Sweden all patients have to be asked consent for storage and further use of biological 
material from clinical procedures. None of the eligible patients in the study had refused 
such use of their samples.  
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RESULTS  
 
Results, Paper I 
The study included 144 paediatric patients with varying diagnoses and varying 
treatment burden before HSCT. Nineteen patients (13%) developed neurological 
complications during the first three months. The background factors of statistically 
significant importance for the development of acute neurological complications were 
the number of positive baseline serologies for herpes viruses (CMV, EBV, VZV, HSV) 
in the recipient and also CMV-positivity alone in the recipient (pre-HSCT was 
associated with an increased risk). The post-transplant  parameters of importance for 
the development of neurological complications were high or low potassium and 
sodium, as well as low calcium (registered as “high” = above or “low” = below 
standard reference values). High levels of bilirubin (>20 Umlol/L) and blood pressure 
above standard age-adjusted reference values were also associated with an increased 
risk. The symptoms of the neurological complications found were seizures (n=10), 
altered consciousness (n=5), headache with nuchal rigidity (n=3) and paresis (n=1). The 
incidents were diagnosed as infectious (n=7), encephalopathy (n=7) and CVS (n=3). In 
two cases the underlying cause of the neurological symptom (seizures in two patients) 
was unknown and the exact cause of the encephalopathy was uncertain in several cases. 
The encephalopathy diagnosis was given if the patient had symptoms and EEG and/or 
neuroimaging results indicating encephalitis/encephalopaty but no other exact cause 
could be found. All the seven patients with encephalopathy had EEG changes 
indicating encephalitis. Only one of the seven patients had CT/MRscan pathology, in 
the remaining sex patients the neuroimaging result were normal (5 patients) or 
missing/not performed (1 patient). The mortality risk for the patients suffering from 
acute neurological complications was significantly higher than for the group without 
neurological complications. 
 
Results, Paper II and III  
In study II the group treated with intrathecal therapy consisted of 74 patients; 56 ALL 
patients and 18 AML patients, with a mean age at HSCT of 9.7 yrs (range 0.5 to 18 
yrs). The group not given intrathecal therapy comprised 46 children, 36 children with 
ALL and ten children with AML, with a mean age of 9.2 yrs (range 1-18 yrs). Fifteen 
percent of the patients given intrathecal therapy had previous CNS leukaemia, 
compared to twenty percent in the other study group. The difference in CNS 
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leukaemia before the procedure was not significant. A similar proportion of the 
patients in the two groups were in bone marrow complete remission (CR), with < 5 % 
blasts, before HSCT. In study II, one patient in each group was identified with 
primary CNS-relapses during the transplant follow up. 
 
In study III the group given intrathecal treatment consisted of 136 patients; 107 ALL 
patients and 29 AML patients, with a mean age at transplantation of 9.2 yrs. The 
group without intrathecal treatment comprised 261 children, 166 with ALL, 89 
children with AML and six children with AUL. The mean age was 8.7 years. Twenty-
three percent of the patients in the group receiving intrathecal therapy had CNS 
leukaemia before HSCT, compared to 13% in the other study group. The difference, 
although noteworthy, was not statistically significant. Patients in complete bone 
marrow remission (CR), with < 5 % blasts, before HSCT was equally distributed 
between the groups.  Isolated CNS relapses were observed in four patients; two 
(1.5%) patients from the group given intrathecal prophylaxis and two (1%) from the 
group without not intrathecal treatment.  
 
In study II, the patients with CNS-relapses had high risk pre-B ALL (intrathecal 
therapy group) and AML M1”high risk” (presenting with a high leukocyte count and 
extramedullar, mastoid, relapse before HSCT) respectively. None of the patients had 
CNS involvement of their leukaemia before the HSCT treatment. Both patients were 
given TBI in their conditioning regimen. The pre B-ALL patient received six 
intrathecal injections after HSCT, but despite this, he developed an isolated CNS 
relapse nine months after transplantation. This patient had also been given CNS 
radiotherapy according to his leukaemia treatment program before HSCT. The AML 
patient suffered a relapse in the CNS within a year of transplantation. Similarly, none 
of the four patients who suffered CNS relapse in study III, had CNS leukaemia before 
HSCT. Three patients had pre-B-ALL HR and one pre-B-ALL IR. Two of the 
patients were given CNS radiotherapy and one received TBI, in the conditioning 
regimen. The time to CNS relapse was 9, 27, 38 and 29 months (mean 26 months for 
all the patients; mean for the intrathecally treated patients group: 18 months, mean for 
the group: 34 months). For one patient in the group not given intrathecal 
chemotherapy after HSCT, the isolated CNS relapse was his/her third relapse after 
HSCT.  
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With one case reported in each group in study II, and two cases in each group in study 
III, neither of the studies showed a statistically significant difference in the incidence 
of CNS-relapse between the groups (p> 0.05). Nor did intrathecal therapy have any 
influence on other types of relapses or survival. The time to CNS –relapse as not 
affected by intrathecal therapy. 
 
As intrathecal therapy is often recommended to patients with a CNS involvement of 
leukemic disease before HSCT (even at centres where it is not given to any other 
patients), the outcome in this subgroup is interesting. Study III included 67 patients 
with CNS involvement before HSCT. Thirty-three of these patients received 
intrathecal therapy after HSCT and 34 patients did not. There were no isolated CNS 
relapses among these patients why we were unable to compare the groups regarding 
this outcome. However it is interesting to notice that despite the absence of intrathecal 
treatment none of these 34 patients had an isolated CNS relapse during follow up. 
When we studied differences in the incidence of overall relapse and death there were 
no differences between the groups.   
 
When assessing neurological complications between the group who was given 
intreathecal therapy after HSCT, and the group that did not receive this treatment, we 
found an equal proportion of neurological complications. In study II, 20% (15 
patients) versus 15% (7 patients) developed neurological complications. In study III, 
11% versus 10% of children had neurological complications during follow up. Both 
studies also made the attempt to detect more subtle sequelae of cognitive type after 
HSCT. These were registered as neurological complications of “cognitive type”, a 
parameter including data on whether the patient was in a school class corresponding 
to his/her age as well as an assessment of ADL score. “Cognitive complications” 
were registered in very few cases; 4 of the 15 patients who had neurological 
complications in the intrathecally treated group in study II. In the untreated group 1/7 
patients had these complications. In study III the corresponding numbers were 7/14 in 
the treated group and 8/25 in the untreated group.  In both studies the majority of the 
children attended a school class that corresponded to their age both at one year after 
HSCT and at the end of follow-up. There were no differences between the two 
groups. The Lansky/ Karnofsky scores for the surviving children were high in both 
studies with the lowest mean figure of 88% at one year after HSCT in the 
intrathecally treated group of study II. In the other patient groups the scores were 
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above 90% in study II and III. None of these three parameters indicated any 
difference in cognitive function between the study groups in these two studies. 
Furthermore, there was no evidence that intrathecal therapy caused an earlier onset of 
complications or that the advent of potential complications was delayed by using 
intrathecal-therapy.  
 
 
Results, Paper IV 
The symptoms and causes of neurological complications in the 20 patients studied were 
in accordance with other studies; headache and seizures were common (18, 211) and 
drug toxicity, suspected or verified, was a frequent cause of neurological complications 
(three suspected drug reactions, and one verified). There were eleven patients (55%) 
were no definite cause was documented regarding the neurological symptoms 
exhibited. Headache with or without fever was the most frequent neurological symptom 
documented (35%), followed by seizures (20%) and confusion/hallucination (20%). In 
four patients, JCV was analyzed in the clinical setting in the CSF drawn, and in one 
patient JCPyV was analyzed in blood at the time of neurological complications. All of 
these tests were negative. In the remaining fifteen patients none of the known PyV‟s 
were found at the time of neurological complications. In three patients, BKPyV was 
analysed at another time point, after HSCT due to symptoms of HC. One of the patients 
had a positive blood sample and was treated with cidofovir. All the 20 CSF samples, 
analyzed retrospectively with PCR, were negative for BK- , JC-, KI-, WU och MC PyV 
DNA. One sample could not be processed for JC/BK virus DNA, as the CSF was 
cloudy and the liquid part of the sample evaporated during the denaturation phase. Nine 
of the 20  patients survived until the end of study period with a mean follow up time of 
3,4 years. This confirms the reduced overall survival after HSCT for patients with 
neurological complications, as seen in other studies  (18).The neurological 
complications were in two cases related to the cause of death, where the neurological 
complication presented as a symptom of leukemic relapse, and cranial herniation 
respectively.  
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DISCUSSION  
Nineteen patients, 13% of the 144 patients in Paper I, suffered from neurological 
complications during the first three months after HSCT. This figure was expected as 
previous studies have shown that neurological complications are common. Since the 
group studied represented several diagnoses and underlying conditions it reflected the 
composition of the patient group at a paediatric transplant centre well. The factors that 
were found to be associated with neurological complications may not increase the risk 
for neurological complications one by one, yet we need to be attentive to all these 
potential risk factors. When coinciding they may be responsible for an elevated risk of 
neurological complications. Electrolyte disturbances and elevated blood pressure are 
known risk factors associated with neurological complications. This was confirmed in 
our study.  The results underline the importance of close monitoring of all vital 
parameters to protect the patients from potentially severe neurological complications.  
Other studies have found GVHD and the use of cyklosporin to be risk factors for 
neurological complications (16, 193). This was not supported by our study. As 
cyklosporin is a well known risk factor, it may very well have been a contributing 
factor to the neurological complications seen in our study. It can be argued that our 
definition of a high concentration (> 250 ng/L) was set too high. We should consider 
that it is not necessarily the high peaks in concentration that create the elevated risks of 
neurological complications. There could indeed be other factors of cyklosporin use, as 
exposure to near toxic doses during a longer time of use, that are responsible for these 
findings. The definition of a high bilirubin level used in the study; 20uM/L, is very 
close to the normal reference value, and might seem low. We chose this level not 
knowing what to expect, as this parameter had not been studied in relation to 
neurological complications before. The bilirubin level increases with liver failure, for 
example due to veno-occlusive disease (VOD). Our interest in studying bilirubin-levels 
relates to the possible link between neurological complications and severe 
complications, such as VOD and GVHD. It has been seen that symptoms from the CNS 
can be the first symptom of multi-organ failure (212, 213). Neither low haemoglobin, 
nor low platelet levels were risk factors in our study, even though CVD was among the 
complications seen. This may be explained by the fact that low haemoglobin and 
platelet levels are rapidly treatable by transfusion and are not allowed to be abnormal in 
the clinical setting for long. Electrolytes on the other hand, can be more difficult to 
correct, with intravenous nutrition or orally administered substitution. Increased risk 
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was seen with a rising number of positive viral serologies of the four herpes viruses 
tested before HSCT. This fact that several positive herpes virus serologies combined, 
pose an increased risk for neurological complications was a previously never reported 
finding. However, the mechanism behind it is probably not surprising; positive herpes 
simplex serology requires aciklovir prophylaxis, and reactivation of viruses calls for yet 
more anti viral treatment, which in turn likely contributes to complications.  
 
In seven patients no other diagnosis or cause of the symptoms than “encephalopathy” 
could be determined, neither in the clinical setting nor in the retrospective study of the 
charts. Neuro-imaging was done in six of the seven patients but only abnormal in one 
patient. As described above; some diagnoses have very distinct changes on MRI of the 
brain. Choosing MRI over CT and/or repeated neuroradiological examination  might 
have facilitated the search for a more precise diagnosis.  
 
In half of the patients who died in the first 90 days in the neurological complications‟ 
group, the neurological complications were the cause of death (3/6 cases). In two of the 
three remaining cases the neurological complication was CVD, where the direct cause 
of death was multiorgan failure, which could in large part be due to the CVD. This lead 
to the major finding of the study, one that is confirmed in several other studies as well: 
that there is an increased mortality risk for patients with neurological complications. 
This result should motivate further efforts to reduce neurological complications in 
paediatric patients after HSCT treatment.  
 
Intrathecal chemotherapy is a treatment which has proved to be essential for primary 
treatment of leukemia in children, largely reducing the CNS relapse rate. Rapid 
progress is made in the field of paediatric oncology and over the last ten years 
survival has increased from 80% to 90% for paediatric ALL (214, 215) Despite this 
progress there is a risk of CNS relapse after HSCT which cannot be disregarded, 
especially in children with previous CNS leukemia. The risk for CNS relapse in these 
children is 17-36% compared to 2-10% in patients without previous CNS leukemia 
(2-10% in ALL and 2-8.8% in AML patients (216, 217)). In the 80s‟ Thompson et al 
showed the beneficial effect of intrathecal therapy after HSCT (56).  Post-HSCT 
intrathecal therapy has subsequently been used frequently, although irregularly, 
among HSCT centers in Europe (57). In study II and III we wanted to examine the 
effect of intratheal therapy after HSCT in patients with modern primary leukemic 
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treatment. The median number of intrathecal injections given after HSCT at the 
centres in the study giving this treatment was six injections. This represents a notable 
increase in exposure to the risks of intrathecal chemotherapy when considering the 
number if injections given in standard NOPHO and other treatment protocols for 
primary leukemia. The NOPHO protocols contain six intrathecal-injections for 
children diagnosed with AML and 16-18 injections for children diagnosed with ALL, 
in primary treatment (22, 218). Our results showed that six intrathecal injections do 
not appear to have the intended protective effect against leukemic relapse in the CNS 
after HSCT. The same year as the publication of paper II, another study was 
published which addressed the same question, and found likewise, that intrathecal 
chemotherapy after HSCT did not have a protective effect against CNS-relapse. In the 
study, written by Oshima et al, the average number of post-HSCT intrathecal 
injections was though only two which may have decreased a potential effect of the 
treatment (175). 
 
Our study material came from six different transplantation centres in Europe where 
different treatment schedules were used, both for leukemia and for the HSCT 
procedure. In examining the differences we concluded that they were not large 
enough to result in bias in the study. Background factors among the patients receiving 
and not receiving intrathecal prophylaxis were evaluated and found comparable. The 
proportion of patients not in complete remission at HSCT, a factor suggested to be a 
risk factor for relapse, was similar in both groups.  
 
In the intrathecally treated group a higher proportion of patients received CNS 
irradiation before HSCT. This difference was significant in study III. This could lead 
to a potential bias with more heavily treated patients in the intrathecal group which 
would falsely strengthen the “effect” of intrathecal therapy. However no effect of 
intrathecal therapy was seen and the risk of bias is thus not relevant for the primary 
end point. The excess complications after intrathecal administration might be higher 
in that group, not due to intrathecal therapy but due to previous CNS irradiation. 
 
One interesting subgroup in the studies was of course the patients with CNS leukemia 
before HSCT, as several small studies recommend intrathecal prophylaxis to this group. 
This recommendation is based on case reports and clinical experience (58, 59, 173, 
175, 178). In our study III 67 patients had CNS leukemia before HSCT and 34 of them 
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did not receive intrathecal chemotherapy. The study sample was unfortunately too 
small to analyze the implications of intrathecal chemotherapy in this group.The fact 
remains though that there were no isolated CNS relapses in the patients with previous 
CNS disease seen during follow up neither for them with intrathecal therapy nor for the 
patients without intrathecal therapy. 
 
The advantages of not giving intrathecal therapy after HSCT are many, both practical 
and psychological. Lumbar punctures cause pain and anxiety in a majority of patients, 
why it should be performed under general anesthesia. When given, the intrathecal 
injection involves the risk of bleeding into the CSF a with a risk of transmitting 
leukemis cells into the CSF well as a risk for CNS infection and subdural haematoma.. 
(219, 220). A study by Menesis et al showed that general anesthesia for short duration 
during painful procedures in children undergoing treatment for malignancies, is safe 
when carried out by trained professionals in outpatient clinical surgery units (221). 
Children who have undergone a  stem cell transplantation generally have a longer 
history of chemotherapy and having gone through a heavy conditioning therapy, they 
are  more vulnerable to both infections and toxicity, than the average pediatric 
oncology patient. Apart from the acute complications of injection, the long-term 
sequeale of intrathecal methotrexate are well-documented.  A higher risk for 
leukoencephalopathy has been seen when intrathecal methotrexate is given after HSCT  
(56).Cytarabine, currently the most common drug used, is not considered to be 
associated with as many complications as methotrexate (182).However, all the 
injection-related risks still apply.  
 
In our studies, we retrospectively tried to detect cognitive complications as well as 
other neurological sequelae, through studying the patients‟ charts. The methods used 
might seem unspecific; however, we concluded that the report of a child attending a 
school class without support and in his/hers correct age group is a relevant parameter 
when estimating cognitive function. The Lansky and Karnofsky scores that were used 
are well recognized. The medical chart in combination with a full medical exam was 
a good basis for assessing a Lansky/Karnofsky score. Although it might not be fully 
applicable to the assessment of neurological sequelae, a patient seriously affected by 
neurological sequelae, would be recognizable (206, 207) Studying these parameters, 
we were not able to identify any difference in the cognitive outcome between the two 
groups, despite the fact that in the intrathecal group 21% received CNS irradiation 
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before HSCT, compared to 9 % in the non-intrathecal group. However, the mean 
observation periods in both studies extended to only four years. The 
Lansky/Karnofsky score showed no differences between the two groups nor were 
there a difference in the number of neurological complications recorded during the 
study period. 
 
In summary, our studies demonstrate a lack of support for the hypothesis that 
intrathecal therapy reduces the incidence of CNS-relapse. The power of the results is 
limited to 80% to detect an absolute difference in outcome of less than 5% between 
the two groups studied. Considering the documented risks of intrathecal therapy, the 
results are strong enough to not support the use of intrathecal therapy for all ALL 
patients and high risk AML patients after HSCT. Each patient should undergo 
individual assessment of suitability and necessity for intrathecal therapy. Finally our 
data indicates that intrathecal-therapy does not increase the risk of cognitive 
complications after HSCT.  
  
Immunosupression is a risk factor for reactivation of viruses such as polyomaviruses to 
which a majority of the population is seropositive since childhood. The three new 
viruses; KI-, WU- and MCPyV have been very scarcely studied in the CNS. Even 
though our sample collection was small, we retrieved CSF samples from 20 patients, 
and this has brought us one step closer to understanding these new viruses. The study 
size was limited by the available amount and number of samples in storage at the 
Department of Virology, Clinical Microbiology, Karolinska University Hospital 
Huddinge. The methods used for detection of PyV DNA are well known and have 
shown reliable results in other studies. The capability of detecting small amounts of 
DNA was good (detection level JC/BKPyV PCR; 10 copies of BKPyV plasmid DNA 
and 5-10 copies of JCPyV DNA, MCPyV PCR: 10 MVPyV copies, KI/WUPyV PCR: 
10 copies). The MCPyV method was newly developed with experience from extensive 
research on PyV in collaboration with Prof Tina Dalianis Research Group, at the 
Department of Oncology-Pathology, Karolinska Institutet, Cancer Center Karolinska, 
the Karolinska University Hospital. A denaturing period had previously been used 
(210) for CSF samples to ensure free viral DNA (if present) in the samples before the 
polymerase chain reaction sequence was started. Primers and positive controls were 
tested in trial-PCR runs previous to tests on our study-samples. As seen in our first 
study (I) and several other studies (17, 88) the causes of neurological complications are 
 52 
often unclear. The cause is often multifactorial but there may also be causative agents 
not yet known or sought for. In order to decrease the number of neurological 
complications, preventable and treatable causes of neurological complications need to 
be studied. In 2007-2008 three new HPyVs were described, and already one of these 
viruses, WUPyV, has been suggested to be linked to the development of PML in an 
HIV patient. If the new HPyV have similar abilities as JCPyV and BKPyV to infect the 
CNS they might be a part of the missing answers behind undiagnosed neurological 
complications in immunosuppressed patients. The patients in our study were all 
immunosuppressed; all LP samples were taken within one year after HSCT (median 
time for LP day +68 after SCT), a majority of the patients had episodes of acute 
GVHD, while a third of them had cGVHD, and was subsequently on 
immunosuppressive drugs. The polyomaviridae family continues to be of interest for 
HSCT clinicians and researchers. The oncogenic potential of MCPyV is highly 
interesting. Data on four new human PyV have been published recently; in late 2010 
and early 2011. The viruses, called PyV 6, 7, 9 and TSV PyV have so far been found 
exclusively on skin but as they belong to the PyV family- we plan to study these viruses 
in the CNS of immunocompromized patients.  
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CLOSING REMARKS AND FUTURE PERSPECTIVES 
 
To conclude, owing to devoted paediatric oncologists worldwide and extensive work 
on international protocols and registries - the progress of paediatric oncology and 
HSCT has made remarkable improvements, both regarding survival statistics and the 
prevention of sequelae. However, more studies on the causes of and prevention of 
neurological complications after HSCT are needed, especially in children.  More 
resources and perseverance in determining causes of CNS-symptoms would be of great 
value to our current patients, and the patients of tomorrow. A widened use of 
documentation with neuro-imaging as well as a broad search for possible viral agents in 
CSF would be of great value. The results presented in this thesis have led to a 
restrictive use of intrathecal therapy after HSCT in our hospital. This will reduce the 
treatment burden, the individual suffering and possibly even the risk of neurological 
complications for the patients concerned. If so, our goal has been achieved. For now.  
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SVENSK SAMMANFATTNING  
Hematopoetisk stamcellstransplantation (HSCT) är en väl etablerad behandling av ett 
flertal benigna och maligna blodsjukdomar, vissa medfödda 
ämnesomsättningssjukdomar och svåra medfödda immunbristsjukdomar. I Sverige 
stamcellstransplanteras årligen cirka 60 barn. Vid en allogen stamcellstransplantation 
erhåller patienten, recipienten, stamceller från blod, benmärg eller navelsträngsblod 
från en besläktad eller obesläktad givare. Patienten får vid så gott som alla HSCT en 
kraftig cellgiftsbehandling med eller utan strålning före infusionen av stamcellerna. 
Behandlingen skall slå ut patientens sjuka stamceller i benmärgen så att de nya 
stamcellerna skall kunna ersätta dem. I efterförloppet efter en HSCT finns risk för flera 
olika typer av komplikationer. Allvarligast är graft versus host reaktioner där de nya 
stamcellerna reagerar immunologiskt mot patientens vävnader. Andra komplikationer 
är infektioner, störningar i hormononsättningen, sekundära cancersjukdomar och 
lungsjukdom. Komplikationer i det centrala nervsystemet (CNS) förekommer hos ca 
15% av patienterna och kan leda till långvariga symptom så som nedsatt kognitiv 
förmåga. Komplikationerna i CNS kan vara orsakade av cytostatika eller andra 
läkemedel, strålning, infektioner och cerebrala blödningar. Allt eftersom överlevnaden 
efter stamcelltransplantation ökar blir förebyggande åtgärder för att minska 
neurologiska komplikationer och deras sena effekter av allt större betydelse särskilt i 
den pediatriska patientgruppen. 
 
Artikel I: Prevalensen av, och orsaker till, akuta neurologiska komplikationer efter 
HSCT studerades i en grupp bestående av 144 pediatriska patienter transplanterade 
mellan 1995 och 2002 på Karolinska Universitetssjukhuset -Huddinge. De 19 patienter 
(13%) som insjuknade i neurologiska komplikationer inom tre månader efter HSCT  
hade en ökad risk för död inom det första året efter HSCT. De riskfaktorer för akuta 
neurologiska komplikationer som identifierades var CMV-seropositivitet hos 
recipienten före HSCT, en ökande risk med ett ökande antal positiva herpesvirus 
(CMV, EBV, HSV och VZV) serologier hos patienten före HSCT, samt 
elektrolytrubbningar, högt blodtryck och förhöjda bilirubinnivåer under de tre första 
månaderna efter HSCT. Det vanligaste neurologiska symptomet var kramper och den 
vanligaste orsaken var infektioner och encephalopati. I flera fall kunde den exakta 
orsaken till komplikationen inte fastställas. 
 
Artikel II och III: Cytostatika given i ryggmärgsvätskan, intratekalt, ges efter HSCT 
för att förebygga leukemiska återfall i centrala nervsystemet hos högriskpatienter. 
Denna behandling kan dock ge upphov till både akuta och sena neurologiska 
komplikationer. Varje lumbalpunktion kan också upplevas som ett trauma för 
patienten. Ingreppet kan även medföra en risk för spridning av leukemiska celler till 
centrala nervsystemet. Effekten av intrathekal behandling efter HSCT visades i en 
studie gjord 1986. Det är dock sannolikt att efter de framsteg som gjorts inom 
pediatrisk onkologi de senaste 20 åren har gjort intrethekal behandling efter HSCT 
överflödig för många patienter. I artikel II och III jämförde vi därför retrospektivt 
risken för återfall i CNS och frekvensen av neurologiska komplikationer efter HSCT 
mellan två grupper av pediatriska patienter som erhållit intrathecal behandling efter 
HSCT respektive ej erhållit denna behandling. I artikel I studerades 120 patienter vilka 
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var transplanterade i Uppsala och Stockholm mellan 1992 och 2005. Vi fann mellan 
dessa grupper ingen skillnad i leukemiska återfall efter HSCT. Denna studie följdes av 
en utvidgad studie med 397 patienter från Sverige, Finland och Nederländerna 
transplanterade mellan 1992 och 2006. Inte heller i denna studie fann vi en ökad risk 
för isolerade CNS återfall om intrathekal behandling ej givits. Risken för neurologiska 
komplikationer var inte större för de patienter som fått intrethekal behandling jämfört 
med dem som ej fått denna. Trots att ingen riskökning angående neurologiska 
komplikationer framkom, kvarstår det faktum att dessa injektioner kan vara mycket 
traumatiska för patienten och är resurskrävande för vården. På basen av resultatet av 
dessa studier har därför rutinerna för intrathekal behandling efter HSCT ändrats på vårt 
och på flera andra sjukhus. 
 
Artikel IV:  
I studie I såg vi ett samband mellan positiva virusserologier och en ökad risk för 
neurologiska komplikationer samt att flera fall av neurologiska komplikationer saknade 
definitiv bakomliggande diagnos. Två typer av polyomavirus (PyV), JC- och BKPyV 
är neurotropa virus vilka kan orsaka neurologiska symptom hos immunosupprimerade 
patienter. PyV -gruppen har vuxit snabbt under senaste åren och nu finns åtta typer av 
PyV. I studie IV ville vi studera förekomsten av PyV i CNS hos tre av de nya typerna 
av PyV samt av JC- och BKPyV samt deras symptom och prognos vid PyV infektion i 
CNS. Vi analyserade sådeles förekomsten av JC-, BK-, KI-, WU- och MCPyV i liquor 
hos 20 patienter vilka haft neurologska komplikationer efter HSCT.  Studien 
genomfördes i samarbete med professor Tina Dalianis och doktorand Geraldine Giraud, 
vid Institutionen för onkologi-patologi/ Cancer Centrum Karolinska, Karolinska 
Institutet/Karolinska Universitetssjukhuset-Solna. Liquor analyserades med PCR. Ingen 
av de fem typerna av PyV kunde påvisas i liquor hos studiepatienterna. Att studera PyV 
efter HSCT är trots detta av fortsatt intresse. Flera nya PyV typer finns också vars 
neurotropa potential är helt okänd. 
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